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SUMMARY
In the first section of this thesis a phytochemical analysis of Mimosa 
tenuiflora P. was undertaken. This plant is claimed to have healing properties and 
the aim of this work was to identify the extractives of the bark.
The second and major part of this volume is concerned with improvements in 
the industrial extraction and in O- and /V-demethylation procedures for some 
important opiate precursors, such as 14-hydroxydihydrocodeinone (oxycodone).
A new synthesis was also developed for noroxymorphone. In this the key 
step is a double oxidation of a derivative of morphine. High yielding routes to 
normorphine and hydromorphone were also developed.
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PHYTOCHEMICAL ANALYSIS OF MIMOSA TENUIFLORA
1.1 Introduction
Mimosa tenuiflora Poir1 (Leguminasae) is a plant that grows in S.E. Mexico. 
The people of Mexico have known for years the medicinal properties of this plant 
which is claimed to have pain-relieving, antibacterial and blood clotting properties. 
Mexican Indians have used this bark in powder form for treating bums and other 
wounds. For intestinal ulcers, the bark is taken as a tea and for skin problems (acne, 
herpes, pimples etc.) the powdered bark is applied as a neutral salve. Face packs are 
made from the powdered bark mixed with egg white, yogurt and rose water and are 
used to clean the face. The mixture is left on the face for 15-30 minutes and then 
washed off with lukewarm water.
Nowadays the plant is protected by decree of the Mexican government. No 
previous analytical work on this plant has been reported, so that a phytochemical 
investigation of the dried, powdered bark of Mimosa tenuiflora was undertaken in 
the expectation that new biologically active compounds would be discovered. Such 
compounds might then be synthesised and studied individually.
Leguminous plants2 contain a great variety of physiologically active 
compounds. However, the plant family is very large and the diversity of extractives 
is such that we concentrated our initial literature survey on closely related plants 
within the Mimosa genus and its allies, particularly those with plants indigenous to 
Central and South America. The most common physiological effect reported for 
extracts of these plants is hallucinogenic activity, thus Fish, Johnson and Homing3 
analysed the seeds and pods of Piptadenia perigrina Benth and P. macrocarpa
-1-
Benth and found that the pods contained A^iV-dimethyltryptamine (1), whereas the 
seeds contained bufotenine (2), bufotenine oxide (3), A^-dimethyltryptamine (1) 
and A^A^dimethyltryptamine oxide (4). The seeds were used by the Indian tribes of 
South America and the Caribbean to make a snuff to use in their ceremonies to 
induce a kind of intoxication in order to contact the souls of the dead. 
A^A^Dimethyltryptamine has subsequently been shown to be a potent hallucinogen 




(2), Ri = OH, R2 = R3 = Me, bufotenine
(5), R1=R2 =H ,R 3 = Me
(6), Rj — OMe, R2 — R3 = Me
-2-
RH
(3), R1=OH,R2 = R3 = Me
(4),R1 = H ,R2 = R3 =:Me
A^N-Dimethyltryptamine seems to be a common component of many other 
Leguminasae species, and it has been identified in Mimosa hostilis Benth,4 a plant 
which is used by Panaru Indians of Brazil to prepare a beverage called ‘wine of 
Jurema’ which is used in their religious ceremonies.
N^V-Dimethyltryptamine (1), N-methyltryptamine (5) and 5-methoxy- 
A^-dimethyltryptamine (6) also occur in Banisteriopsis rusbyana? The addition 
of a single carbon atom is all that is necessary to transform the tiyptamine skeleton 
into that of p-carboline (8), and it comes as no surprise that in many Leguminous 
plants (J-carbolines are observed as natural products. Indeed, N-methy 1-1,2,3,4- 
tetrahydrocarboline (7) co-occurs with the tryptamines in B. rusbyana.
-3-
(8), (3-carboline
Ghosal and Mukheijee have isolated seven indole alkaloids from Desmodium 
pulchellwn Benth6 and noted the presence of A^N-dimethyltryptamine oxide (4) and 
its 5-methoxy analogue (6) in this plant. Significantly, amine oxides of this type are 
considered to facilitate the cyclisation of tryptamines to carbolines and since they 
are known to undergo rearrangement to carbinolamines in vitro this is also thought 
to be the mechanism which operates in vivo.7
Me Me
H
| Me Me 
H
(1)






Rearrangement of tryptamine-N-oxides to 1,2,3,4-tetrahydrocarbolines.
Tetrahydrocarbolines do not give rise to hallucinogenic effects, but they are 
physiologically active and the extracts of the plant Hannoa klaineana from tropical 
Africa, which only contains {3-carbolines is used to treat intestinal disorders.8
Armed with these facts we anticipated that biologically active alkaloids 
would occur in Mimosa tenuiflora, but since claims for antibiotic properties are 
unusual in this plant family, we felt that a search for non-basic components was also 
justified.
1.2 Discussion and Results
The dry powdered bark of Mimosa tenuiflora was defatted with petroleum 
ether (60 - 80°C) and extracted exhaustively with methanol. This on evaporation 
under reduced pressure gave a brown solid (Solid 1). Simple qualitative tests on 
Solid 1 showed the presence of alkaloids (Dragendorffs reagent9 and iodoplatinate 
reagent10) and also carbohydrates (Molische’s test). It was decided to isolate and 
identify the alkaloids first
Solid 1 was partitioned between 2M hydrochloric acid and chloroform and 
the chloroform layer was further extracted with 2M hydrochloric acid. The 
combined aqueous phases were then basified with ammonia and the chloroform 
extracts were washed with water, dried and evaporated under reduced pressure 
(Solid 2). The basified aqueous phase deposited a solid. This basified mixture 
without separating the solid was extracted with chloroform and the residual solid 
(Solid 3) was collected.
Alkaloid
Evaporation of the chloroform layer gave a residue which was 
chromatographed on silica, eluting with chloroform - ethyl acetate - methanol 
mixtures to afford N/Z-dimethyltryptamine as the only alkaloid component of the 
dry bark. Yield 0.4%.
The mass spectrum of this compound exhibits the expected molecular ion at 






The *H n.mj*. spectrum is easily assigned: thus a broad one-proton resonance 
at 5 8.2, removable by deuterium exchange, is that of the proton bonded to the 
indolic nitrogen and a five-proton multiplet between 6 6.99 - 7.63 is associated with 
the four benzenoid protons and the 2-H atom. Two two-proton triplets centered at 6
2.6 and 3.0 (J  = 7.7 Hz) indicate the presence of a -CH2 CH2- group, and the 
chemical shifts of these signals accord well with those anticipated for the resonances 
of the side chain methylene protons of A^-dimethyltryptamine. Finally, there is a 
six-proton singlet at 5 2.35 which relates to the resonance of the N-dimethyl unit. 
We were disappointed not to obtain any other alkaloids and the whole extraction 
procedure was repeated on a large scale. The result, however, was the same.
Aminoacids
The chloroform insoluble "basic” material (Solid 3) was found to be a 
mixture of a-aminoacids and peptides. This constituted about 14% by weight of the 
dry plant material.A solution of Solid 3 in water was analysed for free and bound 
aminoacids using a Hilger Chromaspek Mark II Chromatograph. The free 
a-aminoacids present in the material were found to be aspartic acid, threonine, 
glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, histidine and 
arginine. In order to determine the bound amino acids a solution of solid 3 was 
treated with 6M hydrochloric acid and heated at 105°C for 24 hours. The pH was 
then adjusted to 7 with a sodium citrate buffer prior to chromatography. Three new
-7-
amino acids were found namely serine, trytophan, and lysine. The estimated 
percentages are given in Table 1.
Aminoacid % by weight of 
free aminoacid
% by weight of amino­
acid after hydrolysis
Aspartic acid 2.75 x lO"4 1.46 x lO 3
Serine - 3.97 x 104
Glutamic acid 1.84 x lO"3 4.38 x 103
Glycine 1.02 x 10-4 1.10 x lO 3
Alanine 1.71 x 103 2.07 x 10'3
Valine 2.72 x 104 5.21 x 104
Histidine 1.30 x 10‘2 4.10 x 10'2
Lysine - 3.60 x 104
Arginine 1.60 x lO'2 2.10 x lO'2
Table 1.1
Free and Bound amino acids present in M.tenuiflora bark 
Carbohydrates
A sample of Solid 1 was analysed for carbohydrates by TLC on silica using 
three solvent systems:
(i) rt-butanol-acetic acid-diethyl ether-water (9:6:3:1),
(ii) ethyl acetate-acetic acid-water (6:3:2) and
(iii) H-butanol-acetone-water (4:5:1).
p-Aminobenzoic acid reagent11 was used for detection and methanolic
- 8-
solutions of known carbohydrates (glucose, fructose, galactose, xylose, maltose, 
glucuronic acid, ribose, mannose, raffinose and sucrose) were employed as reference 
markers. The Rf values of the carbohydrates in the plant material were compared 
with those of the above carbohydrates, enabling the identification of glucose and a 
smaller quantity of fructose.
Polvols and Tannins
4Solid 2* was found to consist of polyols and tannins, it was not investigated
further.
Antibiotic Tests
The residue obtained from methanol extraction of the plant material was 
reextracted with boiling water and aqueous extract was evaporated to give solid 4. 
The methanol extract (Solid 1) and the aqueous extract (Solid 4) were sent for 
antibiotic screening. The methanol extract displayed very slight toxicity and weak 
activity with respect to DNA gyrase from E.Coli, HTV Type 1 reverse transcriptase, 
HIV Type 1 proteinase cloned in E.Coli, influenza A, and cell free protein 
elongation in Candida albicans 2005E was noted. Though the aqueous extract was 
active in all the standard antibiotic screens and displayed slight toxicity, it was 
decided that the activity displayed in all of these tests was not high enough to 
continue the investigation.
Conclusion
We are left with the conclusion that the claims made for M.tenuiflora are not 
substantiated by phytochemical evaluation. There is a high sugar and aminoacid 
content in the bark and some antibiotic activity, which is still unaccounted for, but at 
a very low level is noted. We did not recognise any new natural products, but the 
potent hallucinogen N^V-dimethyltryptamine is present at a high concentration. 
Perhaps, after all, it is the action of this compound which has encouraged all the 













2.1 The Alkaloids of Opium
Opium has been used by man for at least 3500 years 1,2 as an analgesic and 
as an agent which induces euphoria. Opium ( the Greek: opion ) is the sun-dried 
exudate of the unripe seed capsule of opium poppy, Papaver somniferum Linnaeus. 
The alkaloid morphine (1), ( named after Morpheus, the Greek god of sleep and 
dreams ) was isolated from opium as a white crystalline solid by a German 
pharmacist, Friedrich Sertiimer as long ago as 1803; opium is still the main source 
of morphine.3 Since Sertiimer’s discovery of morphine many other major and minor 
alkaloids have been isolated from opium and now the number exceeds fifty. Today 
morphine is also derived from ‘poppy straw* ( the dried, milled capsule, after 
removing the seed ) since it is economically more viable to work with the straw than 
to laboriously scar each seed capsule to obtain the exudate. Poppy seed is also 
commercially valuable in the food industry.
RO
N -M e
(1) R = H, morphine 
(4) R = Me, codeine
-12-
Opium contains about one quarter of its weight of alkaloids of which 
morphine forms 42%. The other major alkaloids are noscapine (narcotine, 2, 21%), 
papaverine (3, 18%), codeine (4, 12%) and thebaine (5, 6.5%). The remaining 
















2.2 Opiate activity of morphine and the search for selective drugs.
Morphine is a powerful analgesic (Relative Potency, R.P. = 1) whereas its 
methyl ether codeine is widely used as a mild analgesic (R.P. = 0.1). Morphine is 
also used as an antidiarrhoeal and as a sedative. Because of the unfortunate side 
effects of morphine and its allies, which include respiratory depression, nausea, low 
blood pressure and addictive properties, scientists have been looking for pure 
analgesic agents for many years. Numerous analogues and derivatives of morphine 
have been examined.
An alternative method has been to synthesize molecules having some of the 
structural features of morphine (1) which are believed to represent the active 
sections of the molecule. One such compound prepared in the late 1930s is pethidine
(6) which is used even today for the management of mild to moderate pain.4 
Though it is less potent than morphine its relatively low toxicity level and low 





Methadone (7) is almost identical in pharmacological properties to 
morphine.5 In 1955, further simplified morphines, exemplified by the 
benzomorphans such as (8) and (9) were discovered. They have lower analgesic 










Thus for a few years the trend was to snip away at the morphine structure in 
an attempt to achieve more selective action. The more the simplification process 
goes, the greater flexibility is introduced and in the 1960’s and 1970’s, Bentley 
considered that more rigidity and complexity might be important. Since then 
considerable research has been directed towards the making of rigid molecules.
-15-
Recently a group of peptides has been isolated from brain tissue which act as 
agonists at opioid receptor sites. They are collectively known as ‘enkephalins*.6 One 
of these peptides, methionine-enkephalin (met-enkephalin), (10) has the sequence 
H-tyr-gly-gly-phe-met-OH; another leucine-enkephalin (11) has the same first four 
aminoacids, but is terminated with leucine in place of methionine. It has been shown 
that enkephalins have analgesic potency similar to that of morphine.7
OH
(10), R = CH2CH2SCH3







Diagrammatic representation of one conformation of met.-enkephalin.8
The enkephalins and their allies are the natural opiates, it is a coincidence 
that the morphine molecule has a similar shape as the bio-active conformation of 
these pentapeptides. This recognition has allowed much computer modelling 
experiments to be performed, especially within the pharmaceutical companies, in the 
hope of synthesising stable mimics of the enkephalins which are locked into the 
appropriate geometry.
Not surprisingly, other analgesically active molecules contain rigid 
molecular assemblies incorporating some common structural features to morphine. 
Thus all contain a quaternary carbon atom attached to a benzene ring and a tertiary 
nitrogen atom situated two carbons away from the quaternary carbon atom (Fig. 2). 
The other groups may be aromatic or alicyclic rings. The various substituents of the 
quaternary carbon atom should be bulky to prevent free rotation of the rings.9
-17-
Fig. 2
These requirements for analgesic activity10 of various morphines were 
recognised some years ago and by a consideration of various morphines and 
methadone derivatives, Beckett and Casy11 proposed that the principal features of 
the analgesic receptor sites are:
(1) a flat surface which allows binding of benzene ring of the analgesic drug 
through Van der Waals forces.
(2) a cavity to accommodate the projecting portion of the piperidine ring 
(C-15 and C-16) of morphine.
(3) an anionic site that can form an ionic bond with the cationic nitrogen 
atom (Fig.3).
Though this model adequately accommodates morphine and the 
morphinan-benzomorphan groups of analgesics, modification of the above model of 
receptor site and introduction of new types of receptor sites or subsites are necessary 
to explain the analgesic action of a large number of compounds, especially those in 
which the V-substituent can be varied, 14-substituted molecules, peptide analgesics 
etc. Today evidence from behavioural, pharmacological and biochemical studies 
indicates the existence of at least four receptor classes designated by p., 5, k , and a. 
The pharmacological actions of opiates, as well as those of the three major classes 
of opioid peptides ( [3-endorphin, the enkephalins and dynorphin related peptides ),
-18-













are now thought to occur by an interaction with a combination of these sites.
Portoghese12 suggested that regardless of the binding mode all analgesics are 
involved in ionic bonding with an identical anionic site that may be envisaged as a 
pivotal point around which various modes of binding may occur. A model in which 




For many years opium was processed mainly for morphine by the ‘Gregory 
process’14,15 in which a concentrated aqueous opium extract is treated with 
concentrated calcium chloride solution. This treatment causes the precipitation of a 
‘marc’ consisting of non-alkaloidal material, together with calcium meconate, 
sulphate and lactate. The filtrate on concentration and crystallisation gives ‘Gregory 
salt’ which is a mixture of morphine and codeine hydrochlorides. From a solution of 
the salt in water addition of ammonia precipitates morphine.
More modem methods isolate not only morphine, but the lesser alkaloids 
such as codeine, thebaine, noscapine and papaverine. The principles of extraction 
are based on the relative solubilities of these alkaloids in solutions of different pH 
values. Morphine which has both acidic and basic properties, remains in solution, at 
pH values below 6 and above 12. So opium dissolved in organic solvent, after 
treatment to remove most of the non-opiate materials, is brought to pH 12 with 
caustic soda and partitioned between aqueous phase and organic phases. Morphine 
dissolves in the aqueous phase as a phenate salt while the other alkaloids remain in 
the organic phase as bases. Morphine is recovered from the aqueous phase. The 
organic phase is extracted with a solution of sulphuric acid at pH 2 and then the pH 
of this solution is raised to 6 with caustic soda. Noscapine and papaverine, being 
weak bases are precipitated almost completely between pH 2-6. The filtrate, after 
basifying to pH 10, is re-extracted with a suitable solvent to yield a mixture of 
thebaine and codeine, from which thebaine can be separated as insoluble thebaine 
tartrate, leaving soluble codeine acid tartrate in solution.
MacFarlan Smith Ltd of Edinburgh is the major company in the U.K. which 
produces opiates from opium. The company isolates morphine, codeine, thebaine, 
noscapine and papaverine from opium, while the minor alkaloids, as well as the
-20-
unrecovered major alkaloids, remain in the side streams during the extraction 
process. One of the aims of the company is to identify the minor alkaloids in the 
effluent streams and to find ways of recovering these alkaloids economically. 




Morphine (1), codeine (4) and thebaine (5) are derived biogenetically from a 
suitable 1-benzylisoquinoline derivative.16,17 Tracer experiments have confirmed the 
general hypothesis of Winterstein and Trier18 that these alkaloids are formed by a 
Mannich reaction between 3,4-dihydroxyphenylethylamine ( dopamine, 14 ) and
3,4-dihydroxyphenylacetaldehyde (15) both of which are metabolites of tyrosine 
(12). Since there was doubt about the involvement of 3,4-dihydroxyphenyl- 
acetaldehyde, Leete suggested that the second compound involved in the initial 
Mannich reaction was 3,4-dihydroxyphenylpyruvic acid (16) which is readily 





(12, R = H) 









It was shown by Battersby21,?£at administration of labelled tyrosine-2-14C 
(12) to P.semniferum yielded papaverine (3) labelled at the C-l and C-3 positions.


















This is in agreement with other experiments29 which prove that the C16 
carbon skeleton of papaverine (and morphine) is synthesized in nature from two 
C6-C2 units. It was the recognition that morphine (1) might be related biogenetically
-23-
to the 1 -benzylisoquinoline alkaloids which led Gulland and Robinson,23,24 many 
years ago, to propose the correct structure for morphine. The stereochemistry of the 
alkaloid was confirmed by X-ray analysis techniques by Mackay and Hodgkin.25 
Robinson26,27 also proposed that the hydrophenanthrene ring ( between C-12 and 
C-13 atoms ) in the morphines was formed in the plant by the phenolic oxidative 
coupling of a 1-benzylisoquinoline precursor ( as in 17 ). This suggestion was 
amplified by Barton and Cohen17,28 who argued that the 1-benzylisoquinoline base 
(18) undergoes electron abstraction to form a radical which on intramolecular 
coupling yields the dienone (19).
This hypothesis has been confirmed by radio isotopic labelling 
experiments29,30 which show that norlaudanosoline (17) and its methyl analogue, 
reticuline (18) are precursors of thebaine in poppy plants. Furthermore, reticuline 
(18) undergoes <?-, p- coupling to produce salutaridine (19) and salutaridinol 















































(4), R = Me, codeine 
(1), R = H, morphine
Scheme - 3
-26-
2.5 Synthesis of Morphine
The first complete synthesis of (-) morphine was achieved by Gates and 
Tschudi36,37 in 1952 and modified by Elad and Ginsburg38,39 in 1954.
By the selective introduction of various groups into 2,6-dihydroxy- 
naphthalene (21). Gates prepared a suitably substituted 4-cyanomethyl- 
- 1,2-naphthoquinone (22). This dienophile undergoes Dields-Alder addition with 
butadiene (23) to form the partially saturated phenanthrene (24). On catalytic 
hydrogenation in the presence of copper chromite catalyst, this compound undergoes 
ring closure to the lactam (25). The carbonyl group of (25) is removed by 
Wolff-Kishner reduction and the amide carbonyl group by lithium aluminium 
hydride reduction. These steps are followed by N-methylation with formaldehyde - 
formic acid to give the racemic compound (26). This compound after resolving into 
the positive enantiomer is hydrated with dilute sulphuric acid to give the 6-hydroxy 
compound (27) which is converted to the compound (28) by selective
0-demethylation and then by oxidation with the potassium terf-butoxide- 
benzophenone system. Tribromination of the compound (28) followed by treatment 
with 2,4-dinitrophenylhydrazine (DNPH) produces 1 -bromocodeinone-2,4-phenyl- 
hydrazone from which 1-bromocodeinone (29) is obtained by treatment with acetone 
and hydrochloric acid. During dehydrobromination and the formation of 
a,(3-unsaturated ketone, inversion occurs at C-14 giving the natural stereochemistry.
1-Bromocodeinone (29) is then reduced direcdy to codeine (4) by lithium 
aluminium hydride and demethylation of codeine with pyridine hydrochloride gives 














(i) N2H4, glycol, KOH
(ii)LAH
(iii) HCHO, HCOOH NMe
























(29) (4), R = Me 
(1),R = H
Scheme - 4
The Elad and Ginsburg approach began with the arylcyclohexanone (31) 
which with anhydrous hydrogen fluoride cyclicised to the diketone (32) (Scheme 5). 
The ketonic group in the C-ring of (32) was protected with ethylene glycol in the 
presence of p-toluenesulphonic acid and treatment of the monoketal with amyl 
nitrite in the presence of sodium ethoxide introduces oxime group at C-9 position. 
This on reduction and treatment with acetylglycolyl chloride (CH3COOCH2COCI) 
formed the amide (33). Ketalization of (33) with ethylene glycol and p-toluene 
sulphonic acid effected cyclization as well as 4-O-demethylation to form the 










(iii) Pd/C, H2 
 ►
(iv) AcO CH2 COC1
(31) (32)






































Efforts to obtain morphine by direct biomimetic routes are not successful 
although the supposed intermediate, salutaridine (19) has been prepared from 
reticuline (18) in 0.03% yield by a manganese dioxide oxidation reaction.40 
However, Schwartz and Mamy41 have succeeded recently in oxidising the urethane 
(38) with thallium tristrifluoroacetate to afford a salutaridine derivative (39) in 23% 
yield, and this compound has been converted to thebaine (5).42 (Scheme 6) Thebaine 
can be converted to codeinone43 (40), which in turn can be converted to codeine44 
(4) and then to morphine92 (1).
The morphine - morphinan skeleton can be formed from properly substituted 




Schmidhammer and Brossi46 prepared 6-oxo-N-methylmorphinan (51) from 
an appropriately substituted 1-benzylhexahydroisoquinoline using a Grewe 
cyclization as the key step. They first prepared the 3,4-dihydroisoquinoline
(41),which was O-demethylated with 48% hydrogen bromide to give the 
corresponding hydroxy derivative (42). Reduction of (42) with sodium borohydride 
afforded the tetrahydroisoquinoline (43) and, after resolution of the enantiomers 




(41), R = CH3
(42), R = H
MeO
OH
(44) R = H










(46), R! = CHO,R2 = H
(47), Rj = R2 = H
(48), Ri = CH3, R2 = H
(49), Ri = R2 = CH3






was N-formylated with ethyl formate to form the amide (45). Cyclisation of (45) 
proceeded smoothly in 80% sulphuric acid solution at 25°C and afforded 
N-formyl-2-hydroxymorphinan-6-one (46). Acid hydrolysis of (46) gave (47) which 
was converted into (48) by reductive N-methylation and into the O-methyl ether (49) 
by reaction with phenyltrimethyl ammonium chloride in DMF. A reaction of (48) 
with 5-chloro-1 -phenyl-1 H-tetrazole afforded the ether (50) which on catalytic 
hydrogenation with Pd/C gave the morphinan (51). (Scheme 7b)
Evans and Mitch47 reported a different approach for the preparation of 
morphine - related alkaloids. They found that l-methyl-4-phenyl-l,2,3,6- 
tetrahydropyridine (52) when treated with n-butylithium formed the intermediate 
metalated enamine (53) which on reaction with l-chloro-4-bromobutane formed a











In the studies which followed Evans and Mitch48 used the tetrahydropyridine 
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The perchlorate of (57) on dissolution in methanol and heating gave the 
thermodynamically preferred ris-isomer (58) which with diazomethane afforded the
I
aziridium salt (59). This in turn gave the a-aminoaldehyde (60) and conversion of 
(60) into the morphinan carbinol (61) was effected by Lewis acid catalysed 
cyclization. Methylsulphonation of (61), followed by reduction of the mesylate with 
LiBEt3N afforded the morphinan (62) which could be oxidized to (63) by 
Lemieux-Johnson oxidation with osmium tetroxide and sodium periodate under acid 
conditions.
A modem synthesis of the morphinan system has been devised by Chandler 
and Parsons.49 They have shown that o-allylphenyl magnesium bromide (64) adds 
smoothly to 3-methoxycyclohex-2-enone (65) to give the cyclohexenone (66). 
Reduction of (66) with NaBH4 and CeCl3, followed by treatment with 
dimethylacetamide dimethylacetal gave the amide (68). Ozonolysis of (68) produced 
the aldehyde (69) which on treatment with N-methyl hydroxylamine gave the adduct 
(70). Hydrogenation of (70) in acetic acid using Raney nickel catalyst, followed by 
basification yielded the amine (71). Treatment of the amine with hydrogen chloride 
gas gave a crystalline salt which on fusion furnished the morphinan (72). Reduction
-36-
































In 1987 Toth and Fuchs50 prepared racemic morphine from 2-allylcyclo- 
hexene-l,3-dione and isovanillin in 1.1% overall yield. Isovanillin (74) was 
converted to the dibromophenol (75) and 2-allylcyclohgxene-1,3,-dione (76) was 
transformed into the alcohol (77). Mitsunobu coupling of the phenol (75) with the 
alcohol (77) gave the trans-silyloxy-aryl ether (78) which was desilylated to (79) 
and converted to its epimeric alcohol (80). Treatment of the alcohol (80) with 
n-butyllithium in THF, followed by quenching with ammonium chloride solution 
gave tetracyclic sulphone (81). Catalytic osmylation, followed by lead tetraacetate 
cleavage of the resultant diol afforded the aldehyde (82). Reaction of (82) with 
methylamine hydrochloride and sodium cyanoborohydride in methanol, and 
acylation of the resultant secondary amine with (trimethylsilyl)-ethoxychloroformate
-38-
(TEOC-C1) provided the urethane (83). Swem oxidation of the alcohol, and next 
treatment of the resulting ketone with trimethylorthoformate in acidic methanol 
afforded the enol ether (84), which with potassium rm-butoxide in THF produced 
the dienyl ether (85). Oxidation of (85) provided the racemic dienone (86). Reaction 
of (86) with trifluoroacedc acid gave the dienone-ammonium salt (87) which upon 
neutralization spontaneously underwent an intramolecular 1,6-Michael addition to 
the dienone. The resulting mixture of codeinone (88) and neopinone (89) was 
isomerized to codeinone (88). Sodium borohydride reduction of racemic codeinone 

















s o 2c 6h 5
(78) R = TBDMS





S 0 2C ^ l5
(81), X = CH=CH2
(82), X = CHO






















(4) R = Me 
(1) R = H
Scheme 11
-41-
2.6 Analogues and derivatives of morphine
Despite the valuable analgesic effect of morphine its medical applications 
are restricted inter alia by its addictiveness, which results from its euphoric action, 
and its respiratory depressing properties. This has stimulated a continuing search for 
effective and non-addictive replacements. By 1929 there were 150 derivatives and 
over 300 analogues available. One of the earliest attempts to suppress its undesirable 
effects was acetylation. Thus 3,6-diacetylmorphine ( heroin, 90, RP = 2.5 ), which is 
superior to morphine (RP = 1) as an analgesic and which was thought initially to be 





Codeine is used extensively in various applications that require an orally 
effective, relatively low potency central analgesic (RP = 0.1). It is an effective 
antitussive as well. Since codeine occurs in opium in relatively small amounts, it is 
generally prepared commercially by methylation of the more abundant morphine, 
using methylating agents like dimethyl sulphate, diazomethane and phenyltrimethyl 
ammonium chloride.
Reduction of the double bond in codeine leads to dihydrocodeine (paracodin,
-42-
91), a compound that has found some use as an antitussive agent and it is also an 
analgesic (RP = 0.1). Codeine can easily be converted to dihydrocodeinone 
(hydrocodone, 92) by oxidation of codeine (4) to codeinone (40), followed by 
catalytic hydrogenation. Hydrocodone (92) and its morphine analogue, 
hydromorphone (93) are potential analgesics (RP = 3-4), but fail as drugs because of 









(92), R = Me, Hydrocodone
(93), R = H, Hydromorphone
Another modification has been the introduction of small groups at the 
nitrogen atom of normorphine (94).51 Normorphine itself is found to have a higher 
analgesic effect than morphine. Substituents like propyl, pentyl, hexyl and
-43-
phenylethyl on the nitrogen atom of normorphine give rise to analgesics with higher 
potency.52,53 N-Allylnormorphine54 (nalorphine, 95) and N-allylnorcodeine55 (96) 
were found to have powerful morphine antagonist activity and subsequently used 
clinically in a variety of applications including diagnosis of addiction.
RiO
NR
(94), R1 = R2 = R3 = H
(95), R1=R2 = H,R3 =
(96), R1 = Me, R2 = H, R3
(97), R1 = R2 = H, R3 =
(98), R1 = R2 = H, R3 =
N-(2-Methylallyl) normorphine (97) is a more potent antagonist than 
nalorphine and N-cyclopropylmethyl normorphine56 (98) is about three times as 
powerful as nalorphine as an antagonist and three times as potent as morphine as an 
analgesic.
Metopon57 (5-methyldihydromorphinone, 99) is another compound of 
pharmacological interest. It is orally active and it is about three times as active as 
morphine in relief of severe pain, but usage is restricted because of the expense of 
manufacture. Some potent analgesics which have 6-substitution are desomorphine 
(dihydrodesoxymorphine, 100, RP = 10)58, 6-methyldihydrodeoxycodeine (101)59,60
-44-








(101), R j = R 2 = Me
(102),R1 = H,R2 = N3
Another series of drugs is derived from 14-hydroxy-4,5-epoxymorphinans. 
Thebaine (5) on oxidation gives 14-hydroxycodeinone (103) which is reduced 
catalytically to 14-hydroxydihydrocodeinone (oxycodone, 104). O-Demethylation of 
oxycodone gives 14-hydroxydihydromorphinone (oxymorphone,105) (Scheme 12). 









(103) (104), R = Me
(105), R = H
Scheme 12
Antagonists are developed from 14-hydioxydihydronormorphinone 
(noroxymorphone, 106). Alkylation of noroxymorphone at nitrogen with allyl 
bromide gives N-allylnoroxymorphone62 (naloxone, 107). It is a potent narcotic 
antagonist. In contrast to nalorphine (95) however, naloxone (107) fails to show 
analgesic activity.63 This property has led to its use as a specific antidote for the 
reversal of toxic manifestations of narcotics, particularly in cases of overdoses. 
Analogous compounds, N-dimethylallylnoroxymorphone64 (nalmexone, 108), 
N-cyclopropylmethylnoroxymorphone65 (naltrexone, 109) and N-cyclobutylmethyl- 










Acylation of 3,14-diacetylnoroxymorphone (111) with cyclobutylcarbonyl 
chloride, followed by reduction of both amide and ketone functions with LAH and 
deacetylation gives the drug nalbuphine64 (N-cyclobutylmethyl-14-hydroxy- 

























Nalbuphine is as effective as morphine as an analgesic and it has a low 
incidence of nausea and vomiting, a low frequency of psychotomimetic reactions.66 
14-Hydroxycodeinone (103), on acetylation, gives 14-acetoxycodeinone
(115) which is reported to be a better analgesic67 than the hydroxycodeinone (103), 
but it is more toxic. Extending the alkyl chain length in the ester function at the 
14-position increases the analgesic potency, with the n-pentanoate ester having the 
highest effect. Cinnamoylation at 14-position of oxycodone (104) leads to the ester68
(116) with very high potency (RP = 200). This has led to the speculation that there is 
a receptor lipophilic site in addition to those previously recognised, extending above 
and away from the plane of the opiate C-ring.
-48-
(103), R = H 
(115), R = Ac
(104), R = H, oxycodone
(116), R = COCH=CHPh
As the above account reveals, early efforts centered around derivatisation of 
morphine or the synthesis of simpler structures containing what were perceived to be 
the key pharmacqlhores.69,70 In the event this did not lead to a marked separation of 
desirable and undesirable effects, although some useful drugs were developed from 
these labours. Lack of success prompted another phase of endeavour this time to 
construct more complex rigid analogues of morphine (see page 15). In this way it 
was hoped that the reduced flexibility and subtle differences in overall shape would 
prevent access to some receptor surfaces but not others and lead to a selectivity of 
biological action. The prime instigator of this approach was Bentley71'73 who 
showed that the addition of dienophiles to thebaine (5) gives endo-adducts of the 











(117), R = CHO, COMe, COPh, 
CN, COOR etc.
Scheme 14
These adducts (117, R = COR!) react readily with Grignard reagents74 to 






(118), Ri = Me
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O-Demethylation of these compounds (118, = CH3) affords the
corresponding oripavines (118, R = H) which are more potent than the 
corresponding thebaines. Substitution of the analgesic (118) of N-methyl group by 
N-alkyl units (up to C5), allyl, dimethylallyl, and cyclopropylmethyl (CPM) gives 
compounds with either agonist or antagonist activities and varying degrees of 
potency. Indeed, some of these compounds have analgesic activities many hundred 
times that of morphine with low addiction potential One of such compounds is 
etorphine (119) which has exceptionally high analgesic power75,76 (RP = 10,000).
Etorphine is now only used in veterinary practice because it causes 
considerable respiratory depression in man, even in very small doses. The agonist 
action of etorphine can be reversed by naloxone (107), or diprenorphine (120). 
Diprenorphine is a hundred times as powerful as nalorphine (95) as an antagonist.77 
Buprenorphine (121) with a rm-butyl group in the C-side chain is a powerful 
agonist (RP = 75) and also an antagonist with four times the efficiency of 
nalorphine.78 Buprenorphine is found to be a very effective drug for patients with 
severe pain. No serious side effects have been reported for it.
c 3h 7
R
(120), R = Me, diprenorphine
(119)
(121), R = t-Bu, buprenorphine
-51-
2.7 N-Dealkylation
Although most of the preceding drugs are alkylated at nitrogen, this is not 
always necessary and compounds such as noroxycodone and noroxymorphone are 
important drugs, or drug intermediates. The synthesis of these compounds often 
requires a N-demethylation step which is accomplished in many ways. The classic 
method of N-demethylation is the von Braun reaction79 in which the tertiary amine, 
in a suitable solvent, is treated with cyanogen bromide to form the N-cyanonor 
derivative. This is then hydrolysed and decarboxylated to the corresponding 
secondary amine. The disadvantage with this method is that cyanogen bromide is 
very toxic and also the yields are usually only moderate. An improvement uses 
chloroformates. Thus when a tertiary amine is treated with a chloroformate ester 
(123), a carbamate (124) is formed. On hydrolysis this affords the carbamic acid 




N“” H + HOR + C02
Scheme 15
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This technique was first reported in 1911,80 and ethyl chloroformate81,82 and 
benzyl chloroformate were found to be effective reagents. Later on, however, their 
use has been superceded83,84 and in 1975, Rice85 reported a modified procedure 
using phenyl chloroformate, in which the intermediate N-carbamate ester was 
cleaved with a 1:1 mixture of 64% and 95% hydrazine.
Diethyl azodicarboxylate86 has also been used to N-demethylate thebaine 
and various derivatives of morphine and codeine. 2,2,2-Trichloro- 
ethylchloroformate87 is another reagent used for this purpose and in this case the 
carbamate ester is cleaved with zinc in acetic acid, or in methanol. In 1970s Olofson 
et al** introduced vinyl chloroformate as a reagent for N-demethylation. Though 
reaction times are long, cleavage of the carbamate group is easily achieved and 
clean products and higher yields of products are reported. 1-Chloro- 
ethylchloroformate89,90 (125) is also recommended, and it is reported to give similar 
yields to vinyl chloroformate, but it has the advantage that the intermediate 
carbamate (126) is cleaved by simply warming with methanol (Scheme 16).
°  C1 O Cl
Rl'N -M e  Q  O Me R, + 11 JL -MeCl 
/   ► N " ^ 0  Me  ►
R2 (125) v /  \ M
2 Me Cl
o a
Rix 1 1  JL CH3OH R, OMe
xN O Me ---------► NH.HC1 + C02+ Me—<L




In 1989, Santamaria et al,91 reported a photochemical N-demethylation 
procedure for tertiary amines, specifically alkaloidal types. The reaction occurs 
when the amine, together with a catalytic amount of N,N’-dimethyl-2,7- 
diazapyrenium ion (DAP2* 2BF4 ) in acetonitrile is irradiated while oxygen is 
bubbled through the solution. A 500W high pressure mercury lamp is recommended 
with a glass filter to remove ultra violet rays.
DAP2+ is an electron acceptor excited by visible light, which is not absorbed 
by the amines. In its excited form the reagent abstracts an electron from the lone pair 
of the amine which then undergoes further oxidation to give an immonium ion. 
Hydrolysis completes the reaction.










The conversion of codeine (4) to morphine (1) or codeine derivatives like 
oxycodone (104), hydrocodone (92) etc. to the corresponding morphine analogues 
requires the cleavage of aromatic 3-0-Me group. Though there are a number of 
methods available for O-demethylation, the reagents used in the past are often toxic 
and severe reaction conditions and low yields92,93 (15 - 34%) are commonplace. 
More modem reagents include lithiumdiphenylphosphide, which has been 
recommended for the conversion of trans-codeine and /ra/ty-isocodeine into the 
corresponding morphines,94,95 but some workers have found that this is unreliable. 
Boron tribromide is a reagent of choice for many O-demethylation reactions. It has 
been used previously for the cleavage of methyl aryl ethers96 and the method has 
been developed by Rice97 for the conversion of codeine into morphine. Thioethoxide 
ion98 in hot DMF under nitrogen effects the demethylation of aryl-methyl ethers. 
Other reagents are: sodium benzylselenate," concentrated hydrobromic acid,100 
sodium propylmercaptide101 and trimethylsilyl iodide.102,103
2.9 Synthesis of 14-hydroxy morphine compounds
14-Hydroxymorphines form important semisynthetic drugs, and attempts 
have been made to effect the allylic oxidation of codeine (4) to give 
14-hydroxycodeinone (103). Reagents tried include chromic acid,104 manganese 
(IV) oxide,105 selenium dioxide and terf-butylhydroperoxide.106 In no case is a 









Schwartz and Wallace106 reported the conversion of codeine (4) into 
noroxycodone (131) and then onto noroxymorphone (106). Seven steps were 
involved and the authors claimed a 43% overall yield. According to their scheme, 
codeine (4) was first converted to its N-ethyl carbamate by treating with ethyl 
chloroformate. The product was oxidised to the codeinone derivative (127) with 
manganese (IV) oxide and then converted to the dienol acetate (128) by heating 
under reflux with acetic anhydride and sodium acetate. The dienol acetate on 
oxidation with singlet oxygen in presence of Rose Bengal sensitiser gave 
14-hydroxycodeinone (129), which was reduced to the corresponding 
dihydrocodeinone (130). Finally the 3-0-methyl group and the N-carbamate
-56-
substituent were cleaved in order to obtain the desired product (Scheme 19). The 
N-demethylation step of Schartz and Wallace is, far from satisfactory and the whole 
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(130), R = COiEt (106)» noroxymorphone
(131), R = H, noroxycodone
Scheme 19
The present commercial route to noroxymorphone is from thebaine.107,108 
Thebaine (5) is oxidised to 14-hydroxycodeinone (103) by hydrogen peroxide - 
formic acid mixture109,110 and the enone is selectively hydrogenated catalytically to 
give the corresponding dihydrocodeinone (104). After protection through
14-O-acetylation, N-demethylation is effected by the von Braun reaction with 
cyanogen bromide.111 The resultant N-cyanoderivative (132) is hydrolysed to give 
the secondary amine (133) and this, on acid hydrolysis and O-demethylation by 




h 2o 2/h c o 2h
Thebaine ---------------- ► q
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3.1 An Investigation of the MacFarlan Smith Morphine 
Extraction Process.
In a recent phase of redevelopment, MacFarlan Smith planned to improve 
the process for the extraction of the major alkaloids of opium viz; morphine, 
codeine, thebaine, noscapine and papaverine. They aimed at a process of greater 
efficiency than the existing one, higher recoveries of thebaine and noscapine and the 
isolation of the alkaloids from normally discarded side streams. A flow chart (Fig. 4) 
helps to explain the extraction process showing the inputs, outputs, recycles and 
effluent streams (labelled 1-14). A brief explanation of the process is given below.
1. Opium is treated with ammoniacal industrial methylated spirit (IMS), the 
insolubles are removed and the filtrate is partitioned between aqueous sodium 
hydroxide and a mixture of xylene and amyl alcohol (XAA). The phenolic bases 
dissolve in the aqueous phase at pH 12 while other alkaloids remain in the organic 
phase.
2. The aqueous phase is acidified (pH 5) with sulphuric acid to remove a 
second crop of insolubles which are filtered off. The filtrate is basified to pH 9 with 
sodium hydroxide in presence of XAA causing morphine to precipitate almost 
completely. The solvent layer is removed to give ‘effluent stream (4)’.
3. The XAA phase from step (1) is acidified with sulphuric acid to pH 2 to 
extract basic alkaloids. The XAA fraction separated from the acid layer is 
designated as ‘effluent (10)’. The aqueous acid phase is treated with sodium 
hydroxide until pH 6 is obtained. This treatment precipitates the weak bases -
-60-
noscapine and papaverine.
4. The aqueous fraction after removing noscapine and papaverine is brought 
to pH 10 with alkali and extracted with XAA to remove the remaining non-phenolic 
alkaloids, mainly thebaine and codeine. The XAA extract is treated with 50% 
tartaric acid when thebaine is precipitated as the insoluble tartrate salt Codeine acid 
tartrate remains in solution. Thebaine base is regenerated from its tartrate by 
treatment with ammonia. It is then filtered off and the filtrate is labelled ‘effluent 
(12)’.
5. The aqueous phase containing codeine acid tartrate is made alkaline with 
alkali to pH 10 and extracted with XAA. The organic phase containing (mainly 
codeine) is treated with sulphuric acid at 80°C. Once the XAA phase is separated 
from the mixture it is called ‘effluent (7)*. The aqueous phase (at pH 3.5) is cooled 
when codeine sulphate precipitates; the filtrate is known as ‘effluent (13)*. Codeine 
is regenerated from codeine sulphate by treatment with ammonia.
The effluent streams contain quantities of the major and minor alkaloids of 
opium and are normally discarded. Some of these effluent streams, concentrated or 
dried, were given to the University for analysis. The author’s task was to isolate and 
identify the alkaloids present in these effluent streams, thus allowing an assessment 
to be made as to whether they should be reprocessed or not. We have analysed 
fractions (effluents) (4), (7), (10) and (13).
-61-
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3.2 Minor Alkaloids of Opium
Fraction 10
Since this ‘fraction’ was supplied in large quantity, a lOOg sample of this 
fraction was analysed first. The fraction was extracted with dilute sulphuric acid in 
the presence of chloroform and the acid extract was basified to pH 9 with ammonia 
and extracted with chloroform. The chloroform extract containing the basic 
materials was evaporated to give a dark gummy material. The separation of 
alkaloids from this gum was effected by column chromatography on silica (see 
experimental section). The isolation of pure alkaloids from the crude basic material 
by column chromatography was not easy, as a number of complex compounds of 
plant origin present were eluted together with the alkaloids. Column 
chromatography was repeated sometimes up to five times before pure samples of the 
alkaloids were obtained. The compounds eventually isolated are shown below 
(Table 1) together with yields and Rf values.
-63-
Noscapine (a-Narcotine) (2)
The next compound isolated was proven to be noscapine (2). It was 
crystallised from ethyl acetate as colourless crystals. The mass spectrum of the 
alkaloid gave a base peak at mjz 220 corresponding to the fragment shown below.
5 4
O





The molecular ion peak occurs at mjz 413 in E.I. and in C.I. at mjz 414 
(M+H+). The details of the n.m.r. spectrum of the compound are as follows :
1. Four, three-proton singlets, three at 5 3.86, 4.04 and 4.09 are due to the 
resonances of the hydrogen atoms of the three methoxy functions and one at 5 2.55 
due to that of the N-methyl group.
2. A two-proton singlet at 5 5.94 is characteristic of the resonance of the 
protons of the methylene dioxy group.
3. The 5-H proton resonates at 8 6.31 as a singlet. Two doublets centered at 8
6.08 and 6.96 (J = 8.25 Hz) are the resonances of ortho- oriented aromatic protons 
2’-H and 3’-H respectively.
4. A four-proton multiplet at 8 1.91 - 2.61 is characteristic of the proton 
resonances of the N-CH2-CH2- group.
5. The resonances of 1-H and 9-H give rise to doublets at 8 4.40 and 5.58
-65-
respectively with a coupling constant / 19 = 4.0 Hz. This can be used to estimate the 
dihedral angle as 130° between the two halves of the molecule and hence its 
preferred conformation.114
6. The high field position of 2’-H ( 8 6.08 ) also reflects the fact that the 
adoption of a dihedral angle of 130° between the upper and lower parts of the 






In the infra red spectrum of the alkaloid there are bands commensurate with 
methylene and methoxy groups115 and a carbonyl band at 1708 cm'1. The frequency 
of the latter agrees with the presence of an aromatic five-membered lactone and 
together with the rest of the data, and m.p., led us to conclude that the alkaloid was 
indeed noscapine.116 This was proved by a direct comparison with an authentic 
sample.
Papaverine(3)
The next alkaloid proved to be papaverine (3). This alkaloid gives rise to a 
simpler JH n.m.r. spectrum than that of noscapine (2): four three-proton singlets at 8 
3.77, 3.82, 3.91 and 4.0 which arise from the resonances of four sets of methoxy 
protons and a two-proton singlet at 8 4.54 is associated with that of a benzylic
-66-
methylene group of the papaverine structure (3). Aromatic protons 5-H and 8-H 
resonate at 5 7.05 and 7.35 respectively as singlets, while 3-H and 4-H give rise to 
doublets at 5 8.37 and 7.43 ( 73 4 = 5.7 Hz ) respectively. A three-proton multiplet at 
5 6.74 - 6.83 accounts for the aryl proton resonance of the benzylic group. In the 
mass spectrum, the molecular ion peak is observed at mlz 339 and the base peak is at 
mjz 338 [(M-H)+]. Papaverine has m.p. 147 - 148°C117 and showed no depression in 








The third alkaloid isolated was shown to be thebaine (5); the n.m.r. 
spectrum of which is significantly more complex than that of papaverine. This 
reflects the rigidity of the chiral molecule and hence the non-equivalence of many of 
its protons. Thus, the -CH2-CH2- group of the D-ring of thebaine gives a 
complicated pattern of signals between 8 1.5 and 3.0.
-67-
(5)
Two 2H muldplets centered at 8 1.95 and 2.80 are due to the resonances of 
the protons of the C-15 and C-16 methylene groups. The protons of the N-CH3, 
3-OCH3 and 6-OCH3 groups give rise to singlets at 8 2.48, 3.85 and 3.61 
respectively. A doublet of doublets centered at 8 2.70 is due to the resonance of 
10-Hp, this signal couples with that of 10-Ha ( 8 3.33, / gem = 18.1 Hz ) and with 
9-H ( 8 3.69, J9 10 = 7 Hz ). Protons 7-H and 8-H resonate as doublets centered at 8 
5.56 and 8 5.07 respectively with / 7>8 = 6.5 Hz, whereas 5-H resonates as a singlet at 
8 5.28. The resonances of 1-H and 2-H give rise to an AB quartet at 8 6.50 - 6.66 
( /u = 8.0 Hz).
The mass spectrum of thebaine shows the base peak at mlz 311 which is also 
the molecular ion peak. Once again the identity of the sample of thebaine was cross 
checked by means of an authentic sample.118,119
Codeine (4)
The final alkaloid from the effluent was identified as codeine (4). The JH 
n.m.r. spectrum of codeine has similarities to that of thebaine. Thus the resonance of
15-Hq is double multiplet with / gem = 12.8 Hz. The resonance of 15-Hp is observed 
as a set of doublet of doublets ( / 1516 = 5.1 H z). Similarly the signal for 16-Ha is a 
doublet of doublets ( / gem = 12.6 Hz, 716>15 = 5.6Hz ) whereas that of 16-Hp is a
-68-
double multiplet ( / gem = 12.5 Hz ). The resonance due to 14-H exists as a multiplet 
at 5 2.67 and couples with the signals of 9-H, 8-H and 7-H. The resonances of 9-H 
and 10-H are similar to those of thebaine (see experimental section), that of 6-H is a 
multiplet at 8 4.18 and the signal of 6-OH is a broad singlet at 5 2.9. The resonance 
of 5-H is a doublet at 8 4.9 ( JS 6 = 6.6 Hz ). The resonances of the ethylenic 
hydrogens 7-H and 8-H from C-ring form multiplets centered at 8 5.7 and 8 5.3 





Codeine is of course a familiar alkaloid and one which we expected to find 




Traction 4* (page 61) was analysed in a similar manner to Traction 10*. The 
details of the separation method are given in the experimental section. Even though 
only 4.0g of this sample was available for analysis, nine compounds (eight 
alkaloids) were isolated and identified. These compounds together with the 
corresponding yields and Rf values are given in Table 2.
Compound Rf* % by weight
1 2-(4-Hydroxyphenyl)ethanol (135) 0.96 0.15
2 Noscapine (2) 0.94 3.0
3 Papaverine (3) 0.93 1.6
4 Thebaine (5) 0.74 0.3
5 Narcotoline (136) 0.64 0.2
6 Pa laudine (137) 0.61 1.4
7 Oripavine (138) 0.58 0.25
8 Codeine (4) 0.54 0.5
9 Morphine (1) 0.22 0.4
♦Solvent: CHC13 : CH3COCH3: CH3O H : NH3 = 25:20:5:1
Table 2
The alkaloids noscapine (2), papaverine (3), thebaine (5) and codeine (4) 
were identified by comparing the n.m.r., mass and infrared spectra and the Rf 














This is an uncommon alkaloid clearly related to noscapine (2). Its identity 
was suspected when the n.m.r. spectra of the unknown was compared to that of 
noscapine. The differences in spectra between the two compounds are that there are 
only two three-proton singlets at 5 3.87 and 4.10 for the resonances of two methoxy 
groups instead of the three in noscapine and the protons of the methylene dioxy- 
group in narcotoline give rise to a quartet at 5 5.97 ( / gem = l . |H z )  while those of 
noscapine exhibit as a singlet at 8 5.94. The non-equivalence of the methylene 
protons of narcotoline reflects the chiral nature of the molecule and presumably also 







The mass spectrum of narcotoline also shows a similar fragmentation pattern 
to noscapine, thus the base peak at mlz 206 due to the ion C11H120 3N'‘' is formed by 
the cleavage of the C-l -  C-9 bond. The prominence of the fragment C11H12(>3N+ is 
due to the ease of formation by fission of a bond which is at the same time doubly 


















This alkaloid was also readily identified by its close resemblance to 
papaverine (3). A pure sample of palaudine was obtained by flash column 
chromatography of the crude extract and it was then crystallised from ethanol as 
colourless crystals (m.p. 174 - 175°C).121 The JH n.m.r. spectrum shows 3H singlets 
resonating at 8 3.82, 3.89 and 4.10 corresponding to the proton signals of three of the 
four methoxyl groups of papaverine (3). A two-proton singlet at 8 4.49 is associated 
with a methylene group, and a broad singlet at 8 6.5 (removable by D20  exchange) 
is the resonance of a phenolic proton. Seven aromatic proton resonances from an 
isoquinoline ring and a substituted benzyl group form similar spin-spin patterns to 
those shown by papaverine. The mass spectrum of the alkaloid shows a molecular 
ion with mlz 325 in line with the required structure and as expected an [M — 1]+ 




Alkaloid number 6 proved to be oripavine (138). Its infra red spectrum 
exhibited a broad band at * 3200 cm-1 due to a phenolic O-H and the 1H n.m.r. 
spectrum was very similar to that of thebaine (5), except that thebaine has signals for 
the proton resonances of two methoxyl groups ( at 6 3.61 and 3.85). Oripavine has 
only one which resonates at 5 3.61. This must be located at the terminus of the diene 
system , otherwise such a unit could not survive. The mass spectrum showed the 
presence of a molecular ion of mlz 297 (100%) and it was immediately clear that the 
alkaloid we had isolated was O-demethylthebaine i.e. oripavine. This conclusion 
was verified by comparison with an authentic sample of oripavine.
Morphine (1)
The final alkaloid of ‘fraction 4* was morphine. Once again we expected to 
find this compound and had detected it by TLC at an early stage. Here, as for all the 
other alkaloids, we needed to know how much was present not merely to detect it, 
and some pains were taken to minimise losses during the recovery process.
The *H n.m.r. spectrum of morphine exhibits multiplets between 6 1.7 and 
2.1 which are assigned to the resonances of 15-CH2. Additional signals at 5 2.40 - 
2.55 are due to the resonances of 16-CH2, whereas a doublet of doublets at 5 2.29 
corresponds to the signal of 10-Ha ( / gem = 18.8 Hz and / 10 9 = 6.4 H z ). The protons 
of the N-methyl group resonate as a singlet at 8 2.37. 14-H resonates as a multiplet 
at 8 2.59, whereas 10-Hp generates a doublet at 8 2.96 ( / gem = 18.9 Hz ). A double 
doublet centered at 8 3.32 is assigned to the resonance of 9-H ( J9 10 = 6.4 Hz and 
/ 9 14 = 3.3 Hz ). The 6-OH proton resonance occurs as a broad band at 8 3.07. A 
multiplet at 8 4.12 is due to the resonance of 6-H. The spin-spin pattern for the 
signals of 7-H and 8-H centered at 8 5.56 and 5.24 respectively is that expected of
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the signal couples to 6-H, 5-H and 14-H ( J7 8 = 9.9 Hz ). Finally aromatic protons 
1-H and 2-H resonate as an AB quartet at 6 6.4 - 6.6 ( /  = 8.0 Hz).
It is not surprising that the phenolic opium alkaloids viz, narcotoline (136), 
palaudine (137) and oripavine(138), together with morphine (1), are isolated from 
Affluent (4)’ which is the organic phase separated after precipitating morphine from 
the extract containing all the phenols (see fig. 4).
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Fraction 7
The analysis of ‘Fraction 7* (page 61) showed it to contain, in addition to the 
major alkaloids noscapine (2), papaverine (3) and codeine (4), two minor alkaloids 








Compound Rf* % by weight
1 Noscapine (2) 0.75 0.83
2 Papaverine (3) 0.64 0.33
3 Xanthaline (139) 0.63 0.50
4 Laudanosine (140) 0.59 0.80
5 Codeine (4) 0.30 1.20




Xanthaline122, also known as papavaraldine has a carbonyl group in place of 
the methylene group of papaverine (3). In the infra red spectrum it exhibits vmax 
1640 cm'1 characteristic of a diaryl ketone. The JH n.m.r. spectrum shows four 
three-proton singlets at 5 3.95, 3.96, 3.97 and 4.06 corresponding to the proton 
resonances of the four methoxyl groups. Protons 5-H and 8-H resonate at 8 7.15 and 
8 7.55 respectively as singlets and the resonances of 3-H and 4-H give rise to 
doublets centered at 8 8.46 and 8 7.66 respectively ( / 34 = 5.6 Hz ). A doublet at 8 
6.87 is due to the resonance of 5’-H which is coupled to the signal of 6’-H ( J$\(* = 
8.4 Hz ). A doublet at 8 7.12 due to the resonance of 2*-H is also coupled to the 
signal for 6’-H ( / 2\6* = 1-8 Hz ) which resonates as a doublet of doublets at 8 7.42. 
Apart from chemical shift differences caused by the substitution of the methylene 
group by a carbonyl function the spectra of papaverine and xantholine are similar. It 
is uncertain whether xantholine is a true alkaloid or an oxidation product of 
papaverine. It is however, a common component of opium which has received much 
exposure to atmospheric oxygen both in the “field” and in the processing methods.
Laudanosine (140)
The remaining alkaloid of this fraction was shown to be laudanosine which is 
N-methyl-l,2,3,4-tetrahydropapaverine. The XH n.m.r. spectrum of this alkaloid 
shows a four-proton multiplet between 8 2.48 and 8 2.88 which is due to the 
resonances of 3-CH2 and 4-CH2. A signal for the N-methyl protons and those of four
0-methyl protons give rise to five singlets at 8 2.55 (N-CH3) and 8 3.56, 3.79, 3.84 
and 3.85. The benzylic methylene bridge protons resonate as a multiplet centered at 
8 3.18 unlike the corresponding signals for papaverine (3) and palaudine (137). This 
is a result of the chiral centre at C-l and through coupling with the proton signal of
1-H. In the mass spectrum, cleavage of the benzylic fragment leads to the base peak 













‘Fraction 13’ is water soluble and in order to investigate its contents it was 
taken up in dilute acid and extracted with diethyl ether. Evaporation of the organic 
phase gave no residue. The aqueous phase was then basified and extracted first with 
diethyl ether and then with chloroform. The ether extract on concentrating and 




The chloroform extract contained, in addition to cryptopine, the alkaloids 
noscapine (2), papavarine (3), laudanosine (140), thebaine (5) and codeine (4) 
(Table 4).
Cryptopine (142)
In the *H n.m.r. spectrum of cryptopine, signals due to the resonances of 
5-CH2 and 6-CH2 are observed as a four-proton multiplet at 5 1.6 - 2.6 and those of 
8-CH2 and 13-CH2 appear as another four-proton multiplet at 8 3.55 - 3.65. Two 
methoxyl groups give rise to singlet resonances at 5 3.89 and 3.90 and the resonance 
of the methylenedioxy group occurs as a two proton singlet at 8 5.94. Signals due to
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MeO
Compound Rf* % by weight
1 Cryptopine (142) 0.57 2.5
2 Noscapine (2) 0.75 0.5
3 Papaverine (3) 0.64 1.8
4 Laudanosine (140) 0,59 0.3
5 Thebaine (5) 0.56 0.25
6 Codeine (4) 0.30 2.0
* Solvent CHCI3 : MeOH: NH3 = 90 :1 0 :1
Table 4
1-H and 4-H are exhibited as singlets at 8 7.00 and 8 6.70 respectively. The mass 
spectrum of cryptopine shows a molecular ion at mlz 369, and a base peak 
corresponding to C^HgC^ at mlz 148.
Crytopine is a well known alkaloid investigated many years ago by 
Perkin.123 Like thebaine, cryptopine is something of a chemical ‘chameleon* and 
undergoes a wealth of reactions. Strangely enough Dr. D.W. Brown from this group 
worked on cryptopine for his doctoral thesis124 and so the identity of this alkaloid 




This piece of work represents the first attempt to quantify the ‘wasted’ 
alkaloids from the commercial opium extraction process run by McFarlan Smith 
L td  Although the actual percentage yields in the effluent streams are small the scale 
of the overall process makes their recovery worthwhile provided uses can be made 
of them.
The remainder of this thesis is devoted to utilising of the opium alkaloid 
morphine and some of its derivatives as raw materials for other drug substances.
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3.3 N-Demethylation of Oxycodone
Many modifications of morphine alkaloids have been undertaken and the 
semi-synthetic products have been tested for analgesic/ antagonistic properties. For 
example, N-normorphines serve as important intermediates in the synthesis of many 
drugs. N-Demethylation has always been a problem since reagents used for this 
purpose are often toxic, reaction conditions rigorous and yields of the normorphines 
low to moderate. Several N-demethyladon methods are in use of which the von 
Braun reaction of cyanogen bromide with tertiary amines is one of the oldest Other 
reagents such as diethyl azodicarboxylate125 and various chloroformate esters are 
recommended as replacements for cyanogen bromide and the next project 
undertaken by the author was to assess such reagents applied to the N-demethylation 
of oxycodone (104). This is an important reaction because noroxycodone is an 




(104), Rt = H, R2 = Me, oxycodone
(131), R! = R2 = H
(143), R1 = COMe,R2 = Me
Oxycodone (104) has a free hydroxyl group at C-14 and it is necessary to 
protect this group before attempting N-demethylation reactions. This can be done, 
for example, by acetylation. Thus 14-acetyloxycodone (143) was prepared by
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heating oxycodone under reflux with acetic anhydride.
An *H n.m.r. spectrum of 14-acetyloxycodone (143) was recorded at 400 
MHz. The three-proton singlets at 8 2.19, 2.32 and 3.89 were assigned to the 
resonances arising from the N-CH3, COCH3 and OCH3 groups respectively. A 
one-proton singlet at 6 4.67 is due to the resonance of 5-H and the two-proton 
double doublet at 6 6.64 - 6.72 ( J  = 8.0 H z) is that due to the resonances of the 1-H 
and 2-H protons of the aromatic ring. The rest of the spectrum is quite complex due 
to the presence of two ethano bridging groups forming part of C-ring and D-ring. 
The protons of the -CH2-CH- group of B-ring also resonate in this region. A double 
multiplet at 8 1.54 is due to the resonance of 8-Ha which is coupled to 8-Hp ( / gem = 
11.9 Hz ) and also to 7-Ha  and 7-Hp. The resonance of 8-Hp forms a multiplet at 5 
2.18 ( / gem = 11.6 Hz ). A triplet of doublets centered at 5 1.64 is due to the 
resonance of 15-Ha ( 7gem = 14.6 Hz, / i 5tl6 = 3.7 H z).
When the signal at 8 1.64 was irradiated the triplet of doublets at 8 2.28 
collapsed to a simple quartet. This double doublet of doublets at 8 2.28 is assigned to 
the resonance of 15-Hp. The resonance of 16-Ha is observed as a triplet of doublets 
at 8 2.64 ( / gem = 14.6 Hz and / i 6,i5 = 5.2 Hz ), while that of 16-Hp is exhibited as 
another double doublet of doublets. The signal of 10-Hp is a doublet at low field (8 
3.21) with a large geminal coupling constant ( / gem = 18.6 Hz ). Proton 10-Ha 
resonates at 8 2.5 as a doublet of doublets ( / gem = 18.3 Hz and / 10 9 = 5.2 H z). The 
signal of 9-H is a doublet at 8 4.19, which couples with 10-Ha ( J9 l0 = 5.5 H z). An 
irradiation of the peak at 8 3.2 changed the quartet at 8 2.5 into a doublet. Also, 
when the peak at 8 4.2 was irradiated the quartet at 8 2.5 collapsed into a doublet. 
The final proton assignments were confirmed by a 2D cosy analysis, backed up with 
data from assignments previously made for similar compounds earlier in the project.
For our first experiments to N-demethylate acetyloxycodone we selected 
1-chloroethylchloroformate (125). This reagent89 reacts with tertiary amines to form 
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It has wide applicability and Rj and R2 can be aliphatic or aromatic and may 
be part of a system. Thus O-acetyltropine (144) has been N-demethylated with
1-chloroethylchloroformate to give O-acetylnortropine hydrochloride (145) in 97%
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yield, 6-acetylcodeine (146) to 6-acetylnorcodeine (147) in 97% yield, and
oxycodone (104) to noroxycodone (131) in 86% yield.
OAc
(144), R = Me




(146), R = Me
(147), R = H
14-Acetyloxycodone (143) dissolved in 1,2-dichloroethane was heated with 
1 -chloroethylchloroformate at 65°C for about 20 hours and then at reflux for 2 
hours. After evaporation of the volatiles under reduced pressure, the residue was 
column chromatographed on silica to give the carbamate (148) in about 70% yield. 
An accurate mass determination of the product indicated the molecular formula to 
be C22H24NO7CI. The methyl group of -NCO2CHCICH3 resonates at 5 1.85 as a 
doublet while the proton of -CHC1- resonates in the aromatic region together with 
the signals of the 1-H and 2-H protons ( 5 6.40 - 6.90 ). The N-CH3 peak of 
14-acetyloxycodone at 5 2.45 was not present in the spectrum.
Since the yield of the product (148) was less than that expected, the reaction 
was repeated a number of times under several reaction conditions. Unfortunately we 
have not achieved any better results by changing the solvent, temperature, the 
concentration of the reagent or the reaction times.
The carbamate group was next cleaved by treating N-(l-chloro- 
ethoxycarbonyl)-14-acetylnoroxycodone (148) at reflux in methanol. This gave 
14-acetylnoroxycodone (149) which was then heated with 6M hydrochloric acid at
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100°C for 4-5 hours to hydrolyse the acetyl group and to give noroxycodone (131).
The n.mj*. spectrum of noroxycodone (131) exhibits multiplets between 5 
1.56 and 3.2 for the resonances of eleven protons ( 7-H2, 8-H2, 9-H, 10-H2, 15-H2 
and 16-H2 ). Spin-spin coupling patterns were similar to those of 14-acetyl 
oxycodone described on page ($3). The methoxyl protons resonate as a singlet at 6 
3.90 and the resonance of 5-H gives rise to another singlet at 8 4.66. The 14-OH 
proton resonates at a broad singlet at 8 4.94 and a double doublet at 8 6.62 - 6.73 ( /  
= 8.2 H z ) is due to the resonance of 1-H and 2-H. The IR spectrum of noroxycodone 
shows a broad peak at 3200-3500 cm'1 (OH and NH) and a sharp band at 1718 cm'1 
(CO).
The best overall yield we obtained for the conversion of oxycodone to 
noroxycodone was 68 - 69%, though the literature claim is 86%. However, we find 
that if the N-demethylation experiment is carried out without purifying any of the 
intermediate compounds, an overall return of material representing 85 - 88% of the 





(148), Rj = COMe, R2 = C02CHC1CH3
(149), Rj = COMe, R2 = H
(150), Rx = COMe, R2 = C02CH=CH2
-86-
RA.Olofson et al,127 used vinyl chloroformate128,129 for the selective 
N-demethylation of tertiary amines. We tried this reagent for the N-demethylation of 
oxycodone. First 14-acetyloxycodone (143) was prepared and a solution of it in 
1,2-dichloroethane was treated with vinyl chloroformate at 50°C. The reaction is 
very slow. So heating the mixture for 4-5 days with 10 molar equivalents of vinyl 
chloroformate became necessary for the completion of the reaction. Eventually, 
however, N-vinyloxycarbonyl-14-acetylnoroxycodone (150) was obtained in high 
yield and this was dissolved in dichlormethane and reacted with hydrogen chloride 
gas. When the solvent was removed and residue heated at reflux with methanol the 
carbamate group was cleaved off. Eventually the O-acetyl group was removed by 
the procedure described earlier, or by heating the product 14-acetylnoroxycodone 
with 25% sulphuric acid at 100°C for 5 hours. In either case noroxycodone
was prepared in * 88% yield.
In 1972 Abdel-Monem and Portoghese130 reported the use of phenyl 
chloroformate131 for the N-demethylation of morphine and codeine. They treated 
morphine with phenyl chloroformate in presence of potassium carbonate in boiling 
chloroform to obtain N-phenoxycarbonylnormorphine (151). The carbamate group 
of this compound was then removed by reaction with ethanolic potassium 
hydroxide. This method was revised by Rice132 who used a 1:1 mixture of 64% and 
95% hydrazine to cleave the N-phenoxycarbonyl group.
Later, Rice and May133 found that either normorphine or norcodeine 
prepared by this method were contaminated with a small quantity of the 
corresponding dihydro derivatives formed by reduction with hydrazine. They then 
modified the procedure and according to their revised method, a mixture of 
morphine, potassium carbonate and chloroform was heated under reflux for 20 
hours. After filtration, the solvents were evaporated'and the product mixture was
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(151)
treated with 95% hydrazine under reflux for 7-8 hours. The final product was then 
isolated from the reaction mixture.
Oxycodone was thus N-demethylated by using phenyl chloroformate 
according to the modified procedure of Rice, a 56% yield of noroxycodone was 
obtained.
Ethyl chloroformate,81 benzyl chloroformate and 2,2,2-trichloroethyl 
chloroformate87 are three other chloroformates used for N-demethylation. When we 
tried to demethylate oxycodone by heating it under reflux with a mixture of ethyl 
chloroformate, potassium carbonate and chloroform for a week, we found that the 
N-carbamate ester was formed only in 15 - 20% yield.
Montzka et a/.,134 recommended 2,2,2-trichloroethyl chloroformate as a 
demethylating agent, employing a procedure similar to that used with phenyl 
chloroformate.130 Here the intermediate carbamate is cleaved by reduction with zinc 




Many natural products contain aryl rings bearing methoxy groups and 
although phenols are metabolised first either by the ‘shikimate’ or the ‘acetate’ 
biosynthetic pathways, O-methylation of the products through the agency of 
S-adenosyl methionine (or an equivalent) is a frequent final step. Often the methyl 
ether is then released from the assembling enzyme system without further 
elaboration.
O-Demethylation of aryl methyl ethers is not normally a biosynthetic 
process, but it is one often required synthetically. In our case we were asked to find 
a commercially viable means of converting oxycodone (104) into oxymorphone
(105). The latter compound is a very useful starting material for a range of opiate 
drugs. Clearly the need was for a high yielding reaction involving a relatively 
non-toxic reagent. From the long list of possible O-demethylating agents our first 
selection was lithium iodide,135 which under anhydrous conditions is known to 
cleave aryl methyl ethers. This reagent is easily handled and is normally used in 
conjunction with a base, such as 2,4,6-collidine. Harrison,136 for example, claims a 









When we applied this reaction to oxycodone, however, only starting material 
was recovered.
Trimethylsilyl iodide137 is another recommended reagent It is known to 
cleave alkyl aryl ethers and alkyl esters when they are heated together in an aprotic 
solvent such as carbon tetrachloride or deuteriochloroform at about 50°C. Yields are 
claimed to be very high (80 - 95%). It was observed by other workers that the 
reaction is less successful for aryl methyl ethers although phenols have been 
obtained in moderate to low yields.138 The mechanism of the reaction is as follows.
O -S i-M e Me
I




When applied to oxycodone, however, the maximum yield of oxymorphone 
obtained was 15 - 20%, the remainder being recovered starting material.
A modification of the reaction, due to Olah,138 requires that trimethylsilyl 
iodide is replaced by phenyltrimethylsilane and iodine. This has been superceded, 
however, by the use of a mixture of chlorotrimethyl silane and sodium iodide.139 
Disappointingly, neither process is satisfactory for the demethylation of oxycodone.
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Lithium diphenylphosphide140 was tried next. The reagent was prepared by 
treating chlorodiphenylphosphine with lithium metal in dry THF and stirring the 
mixture for 2 hours. The recommended literature procedure141 for demethylation of 
aryl ethers is to heat the ether in dry THF with lithium diphenylphosphide reagent.
PhOMe + Ph2P-U + ------► PhO' + Ph2OPMe + Li +
When reacted with oxycodone lithium diphenylphosphide produced at least 
five compounds as seen by TLC analysis of the product mixture, none of which 
corresponded to required oxymorphone (105).
Of course, hydrogen bromide100 has proved to be an effective reagent for the 
fission of many type of ethers and it is claimed to be effective for the conversion of 
oxycodone (104) into oxymorphone (105). When we repeated the reaction with 
oxycodone, the yield of oxymorphone was 61% with 17% unchanged oxycodone 
recovered.
Boron tribromide142'145 is another reagent widely used for the purpose of
O-demethylation. Rice97 reports that codeine can be O-demethylated to morphine in 
90% yield by treatment with boron tribromide in chloroform at room temperature. 
The reaction time is only 20 minutes. When we tried the reaction upon oxycodone 
we obtained oxymorphone in 50% yield and it was not possible to improve upon this 
productivity by altering the conditions. Boron tribromide, like hydrogen bromide, is 
toxic and corrosive and one reason we were commissioned to do this study was to 
attempt to avoid the use of such reagents.
Fusion of codeine with pyridine hydrochloride at 190°C provides morphine 
in low yield. This method has been used by Rapport44, by Gates37 and by Goto146 in
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synthetic routes to morphine. Unfortunately, the separation of the phenol from the 
spent reagent is not simple and this tends to limit the yield of morphine to 15 - 34%. 
Applied to the conversion of oxycodone to oxymorphone we obtained only to a 10% 
yield of the required compound A similar yield was recorded when oxycodone was 
treated with propane-thiol in dimethylformamide a procedure recomended by 
Lawson and DeGraw101 for similar molecules.
At the end of this investigation we found that for the O-demethylation 
process we were unable to recommend any better reagent than hydrogen bromide, 
and even so a mixture of product and starting material was produced. A similar 
situation was presented by N-demethylation, although here, at least, the reagent
1-chloroethylchloroformate seemed to offer a reasonable yield of noroxycodone 
from oxycodone.
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3.5 Separation of noroxycodone (131) from a mixture containing 
oxycodone (104)
Separation of products and starting materials is a common enough problem 
to industrial companies and frequently unreacted compounds are simply recycled. 
We used column chromatography to separate our mixtures but this technique is not 
viable on a commercial scale except for very valuable chemicals. Drs. Brisdon and 
England147 at Bath have shown that it is possible to separate protonated secondary 
amines from tertiary amines by liquid-liquid extraction. A dilute solution of the 
amines is acidfied and extracted with 12-crown-4 functionalised polysiloxanes
The polysiloxane provides a mobile hydrophobic phase and the crown ether 
bonded to it ‘captures’ the conjugate acid of the secondary amine by hydrogen 
bonding (Fig. 8). This technique has been used at Bath to separate codeine and 
norcodeine.
(153).
CH3 c h 3




Protonated secondary amine - polysiloxane complex 
Fig 8..
The method works best for solutions containing 1% of the bases, but it can 
be made continuous and in principle as pure materials are removed, more mixture 
can be added. We sought to use the technique to separate oxycodone and 
noroxycodone, but we were very disappointed to find that using HPLC to analyse 
the extent of separation only 6% of the noroxycodone was taken up by the 
polysiloxane/crown after a period of 24 hours as against the 25% separation reported 
of norcodeine from a codeine-norcodeine mixture.
A variant of the method uses a membrane of the polysiloxane/crown to 
separate two aqueous phases. One of these contains the amine mixture, but with time 
the secondary amine, which in its protonated form binds initially to the membrane 
surface, translocates through the membrane and passes into the hitherto amine free 
compartment. In a sense, this has analogies with osmotic separations and it is 
necessary to continually remove the secondary amine by solvent extraction so as to 
maintain a concentration gradient between the solutions.
We have as yet not fully investigated this procedure, but our initial attempts 
were not encouraging and probably reflect differences in basicity between 
noroxycodone and norcodeine itself.
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3.6 A New Synthesis of Noroxymorphone
The introduction of 14-hydroxyl group into morphines enhances their 
analgesic activity. 14-Hydroxydihydromorphinone (oxymorphone, 105) is a 
powerful analgesic and its N-nor analogue, 14-hydroxydihydronormorphinone 
(noroxymorphone, 106) is an important intermediate for naloxone (107), nalmexone 
(108), naltrexone (109) etc. Some of these products are pure antagonists, while 
others have mixed agonist-antagonist properties.
There are two established methods for the preparation of noroxymorphone, 
one due to Schwartz and Wallace (Scheme 19) (see p. 58) utilizes codeine as the 
starting material, while the other begins with thebaine (Scheme 20) (see p. 59). The 
latter is used commercially, despite the fact that thebaine is expensive and relatively 
unstable. This uses toxic cyanogen/nfetfiodalso.
Our aim was to prepare noroxymorphone by a method suitable for industrial 
use from another source other than thebaine. Since O-demethylation of codeine is 
difficult to achieve, the obvious choice of starting material is morphine. Morphine is 
also the most abundant alkaloid of opium and hence the cheapest.
If morphine is selected then the following steps were envisaged:
(1) Selective protection of the phenolic hydroxyl group.
(2) Oxidation of the alcoholic group to the corresponding ketone.
(3) Reduction of double bond of ring C.
(4) Introduction of hydroxyl group at C-14.
(5) N-Demethylation, perhaps after protection of the C-14 hydroxyl group.
(6) Deprotection.



























Step 1 is required since oxidation of morphine is known to give complex 
mixtures. The problem is the phenolic nature of the alkaloid, a fact substantiated by 
the observation that its O-methyl ether, codeine, is oxidised without difficulty. We 
have commented already that codeine is not a good starting material yet we were 
precluded from O-acylation since this gives rise to schedule 1 derivatives.
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3,6-Diacetyl morphine, for example, is better known as "heroin".
Our choice was thus a silyl protecting group which has the advantage of easy 
removal. One widely used reagent is r-butyl dimethylsilyl chloride which reacts with 
both alcoholic and phenolic hydroxyl groups in the presence of a base to yield the 
appropriate f-butyldimethylsilyl (TBDMS) ether. This has been used by Arzeno et 
a/.148 and by Matthews and Sainsbury149 to protect the 6-OH group of codeine. In 
practice the reaction works well and in the presence of two equivalents of imidazole 
in dimethylformamide solution a 70% yield of 3,6-bis (TBDMS) morphine (154) 
and 22% yield of 3-TBDMS morphine (155) were obtained. Here two equivalents of 
TBDMS chloride were used; but when this concentration was raised to three 
equivalents and the proportion of imidazole was increased to five equivalents the 
isolated yield of the disilyl ether (154) was 98%. Furthermore, no heating is required 
and simply stirring the reaction mixture under a nitrogen atmosphere overnight is 
sufficient. Physical data for the product are provided in the experimental section.
NR
154, Rx = R2 = TBDMS, R3 = Me
155, Rx = TBDMS, R2 = H, R3 = Me
156, Rx = R2 = CH2=CHCO, R3 = OCOCH=CH2
157, Rj = R2 = TBDMS, R3 = OCOCH=CH2 
94, R! = R2=R3 = H
-97-
Normorphine
With this doubly protected compound to hand we tried to change the order of 
reactions previously outlined and attempted a N-demethylation experiment upon it. 
Olofson et al.150 have effected N-demethylation of morphine itself using vinyl 
chloroformate as reagent This gave 3,6-dihydroxy protected N-vinyl carbamoyl 
morphine derivative (156) in 91 % yield, but this compound had to be N-deprotected 
by treatment with hydrogen bromide, prior to the removal of the 3-0- and 6-0- 
substituents by hydrolysis with dilute hydrochloric acid. The last reaction required 8 
hours. When we reacted the disilyl ether (154) with vinyl chloroformate we were 
pleased to find that 3,6 bis (TBDMS)-N-vinyloxycarbonylnormorphine (157) was 
obtained in quantitative yield. This product could be converted into normorphine by 
either of the following methods.
(a) The carbamate (157) in dichloromethane solution was treated with 
hydrogen chloride gas and the solvent removed by evaporation under reduced 
pressure. The residue was then warmed with methanol.
(b) The carbamate was simply heated with methanol containing a few drops 
of concentrated hydrochloric acid.
Either way the product normorphine (94) was isolated in greater than 95% 
yield. In a separate experiment, 1-chloroethyl chloroformate was used as the 
demethylating agent and a 80% yield of normorphine was obtained, details of the 
experiment are given in the experimental section.
In some other reactions an attempt was made to N-demethylate the disilyl 
ether (154) with f-butyl hydroperoxide in the presence of a catalytic amount of 
ruthenium (II) tri(triphenylphosphine)dichloride [RuG2(PPh3)3]. This reagent 
combination has recently been introduced by Murahashi et al.151 for the 
demethylation of N-methyl tertiary amines. However, it totally failed to effect any 
N-demethylation of the disilyl ether (154), even after it was heated under reflux with
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the reagent and catalyst in benzene solution for 3 hours.
Attempt to introduce diene system in C-ring
We also considered the possibility of introducing a diene system into ring-C 
of the 3,6-bis (TBDMS) morphine (154) in the anticipation that we might be able to 









This type of reaction is known to occur with thebaine (5) where it is 





















If successful this should afford the corresponding silyloxydiol (160) which 











One way to insert the diene system would be to brominate the disilyl ether at
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One problem with this approach, is highlighted in the above scheme, namely 
the a-orientated bulky silyloxy group at C-6 would dictate the formation of a 
(3-bromonium ion intermediate. If bromine itself was the reagent then this would 
lead to the fra/LS-dibromide and thus the expected product would be the monobromo 
compound (164) rather than the diene (158) since it is not possible to attain the usual 
trans antiperiplanar transition state geometry for the elimination of the second 
molecule of hydrogen bromide.
In the event, bromination of the disilyl morphine (154) with 
N-bromoacetamide in methanol at 0°C gave a monobromo derivative 
C29H46Si2BrN03 in 33% yield. The *H n.m.r. spectrum of this compound exhibited 
a one proton singlet at 5 6.84 in place of the AB double doublet ( 5 6.4 - 6.8 ) 
expected for the 1-H and 2-H resonances of the disilyl ether. No other significant 
changes in the spectra of the starting material and product were noted suggesting 





The formation of the 1-bromoderivative (164) did not encourage us to 
proceed with this route.
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Oxidation
At this point we returned to our original plan namely to oxidise 3-(TBDMS) 
morphine (155) to 3-(TBDMS)morphinone (165) (Scheme 31). This requires 
selective deprotection of the disilyl ether (154) and this posed a problem. This 
difficulty was solved by forming the anion of morphine, through reaction with 
sodium ethoxide, and treating it with 1.5 molar equivalents of TBDMSCl. No 
imidazole was added. The yield of 3-(TBDMS) morphine (155) obtained was 99% 
and it is noteworthy that if only 1.1 molar equivalent of TBDMSO are used the 
yield falls to 91%. The n.m.r. spectrum of the product exhibits the 6-hydroxyl 
proton signal as a broad doublet at 5 2.81, but in other respects the chemical shifts 










Oxidation of 3-(TBDMS) morphine
A mild cheap oxidising agent for allylic alcohols is manganese (IV) oxide, a 
reagent which is easily removed at the end of the reaction and which is far less of an 
environmental hazard than, say, a chromium based oxidant.
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When a chloroform solution of 3-(TBDMS) morphine (155) was stirred for 
30 minutes with ‘activated* manganese (IV) oxide, TLC analysis ( Silica, CHC13 : 
MeOH = 9 : 1 )  showed that two compounds had been formed. After 48 hours, 
however, a single product was present This compound exhibited a molecular ion 
peak at m/z 413, 16 mass units greater than expected for the morphinone (165). 
Hydroxylation as well as oxidation to the 6-hydroxyl group was indicated and the *H 
n.m.r. spectrum revealed a simplified set of resonances for the signals of 7-H and 
8-H. In the starting compound these occur as multiplets centered at 5 5.30 and 5.70 
while in the new compound they form two simple AB related doublets ( /  = 10.1 Hz) 
at 56.16 and 6.61.
The multiplicity of 8-H resonance in the starting material is in part due to 
spin-spin coupling to the signal of 14-H, thus since we were anticipating oxidation 
of the 6-hydroxyl group to a carbonyl group with the evitable loss of 6-H, the cause 
of the spectroscopic change must be the formation of the hydroxyenone (166). The 
formation of such a product would, of course, explain the downfield shift of the 
signals of 8-H and particularly 7-H.








Indeed reference to the spectrum shows that a signal for 14-H is absent and 
that of 9-H is now a doublet at 5 3.03 ( J -  5.9 Hz ) coupled only to the signal of 
10-H. A broad exchangeable (1H) resonance is present at 5 5.4 due to the 
14-hydroxyl proton and further proof that we have made the correct structure 
assignment comes from the infra red ( vmax3340, 1670 cm'1 ) and the 13C n.m.r. 
spectra. In the latter a new singlet peak occurs at 5 68 whereas normally the 
resonance of C-14 occurs as a doublet at 8 40 - 41.
This result was extremely pleasing for we had succeeded in bringing about 
what we might have anticipated as the single most difficult step in the synthesis of 
14-hydroxydihydronormorphinone.
We envisage that this must be a radical mediated reaction and that after 
oxidation at C-6, the C-14 position is oxidised. Perhaps a hydroperoxy radical is 
formed which then decomposes to a hydroxyl group. Such allylic oxidation 























Our enthusiasm for this chemistry was only tempered by the low yield of 
35%. Two options were open either: (a) to try and improve the oxidation step, or (b) 
to seek an alternative route.
We noted that codeine (4) can be easily oxidised to codeinone (40) by 
treatment with chromic acid. The ketone can then be converted into the dienamine
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(167) by reaction with pyrrolidine in the presence of p-toluene sulphonic acid;152 
and this product may then be oxidised with 30% hydrogen peroxide-formic acid to 



















We were encouraged by this result and considered applying to the oxidation 
of 3-(TBDMS) morphinone (165). The starting material was prepared by treating 
3-TBDMS morphine (155) in chloroform with manganese (TV) oxide. When the 
reaction mixture was stirred at room temperature for 15-20 minutes it was noted that 
most of the starting material was converted into the corresponding ketone. (Rf = 
0.43, CHC13 : MeOH = 9:1) together with a small amount of the
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14-hydroxymorphinone (166) ( Rf = 0.55, same solvent system ). These could be 
separated by flash column chromatography to give approximately 90% yield of 
3-TBDMS morphinone (165). The IR spectrum of this compound showed a strong 
carbonyl band at 1667 cm'1 and in the !H n.m.r. spectrum the 5-H proton resonance 
is seen as a singlet at 8 4.66. The signal for 7-H is a doublet at 8 6.63 ( / 7 8 = 10.4 Hz 
) and that of 8-H is a doublet of doublets at 8 6.07 ( / 8 7 = 10.3 Hz and / 814 = 2.8 Hz 
). Other features of the spectrum are similar to those of the starting compound.
TBDMSOTBDMSO
MnO




Alternative ways of generating 3-TBDMS morphinone were also tried, but 
were generally far less satisfactory. For example, an oxidation with selenium 
dioxide gave only 15% of product, but a combination of selenium dioxide and 
r-butyl hydroperoxide afforded 43% of the morphinone (165), plus 10% of 
14-hydroxy-3-TBDMS morphinone (166).
Tetra-rt-propyl ammonium perruthenate (TPAP) has received much publicity 
as an oxidant153,154 for alcohols. An oxidation using this reagent in the presence of 
N-methylmorpholine-N-oxide gave an 86% yield of the morphinone (165), but 
overall this is less efficient than using the inexpensive manganese (IV) oxide.
3-TBDMS morphinone (165) was next converted to the dienol acetate (168)
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by heating it under reflux with freshly fused sodium acetate and acetic anhydride for 






An attempted oxidation of the dienol acetate (168) with hydrogen peroxide in 
a sulphuric acid - formic acid mixture did not give the 14-hydroxymorphinone (166) 
or any other tangible product.
We thus returned to the direct oxidation of 3-TBDMS morphine (155) to 
(166) with manganese (IV) oxide, and sought to improve upon the previous yield. 
This reaction was repeated under a number of different reaction conditions, thus 
different solvents such as dichloromethane, tetrahydrofuran, acetone etc., were tried, 
but it was found that no advantage was to be gained over the use of chloroform. 
When carefully dried chloroform was used as solvent and the reaction was carried 
out under nitrogen, we discovered that oxidation had taken place only to a limited 
extent, even after stirring the reaction mixture for two days.
Activated manganese (IV) oxide (Attenburrow oxide) was next prepared 
according to the literature method155 and used in the reaction. This proved less 
efficient than the commercial sample of activated manganese (IV) oxide as supplied 
by Aldrich Chemicals. This gave a better yield and a cleaner product
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The conversion of 3-TBDMS morphine(155) to 3-TBDMS- 
14-hydroxymorphinone (166) takes about two days to complete with ordinary 
stirring of the reaction mixture. When the reaction was carried out with an ultrasonic 
vibrator, the starting material decomposed. Repetition with varying amounts of 
manganese (IV) oxide showed that at least 8-10 times (the weight of morphine) 
oxidant was necessary to minimise the reaction time and to optimise the yield. 
Interestingly, when 2-3 drops of hydrogen peroxide were added to the reaction 
mixture and the reaction was followed by TLC for 3 days only partial conversion to 
the 3-TBDMS morphinone was noted. No 14-hydroxyl-3-TBDMS morphinone 
(166) was formed. Manganese (IV) oxide and hydrogen peroxide react to produce 




Indeed when the mixture containing 3-TBDMS morphine and 3-TBDMS 
morphinone was stirred with some 4A molecular sieves and left stirring overnight 
both compounds were oxidised to 14-hydroxy-3-TBDMS morphinone (166).
When the oxidation process, without hydrogen peroxide, was carried out in 
presence of molecular sieves, oxidation to the 14-hydroxymorphinone was complete 
within a day and the yield was increased to about 40%. Some anhydrous sodium
-110-
carbonate present in the reaction mixture did not favour the formation of 
14-hydroxymorphinone, but the addition of silica gel increase the speed of reaction 
as well as the yield of 3-TBDMS-14-hydroxymorphinone.
We noted that the oxidation reaction is temperature dependent Increasing 
the temperature increases the rate so that in chloroform at reflux 3-TBDMS- 
14-hydroxy morphinone was formed quickly, but the yield was lowered through 
decomposition. Repeating the experiment at various temperatures showed that the 
maximum yield of 14-hydroxymoiphinone was achieved at a temperature of 
35-38°C in the course of 3-4 hours.
These experimental results helped us to define the optimal conditions for the 
preparative method:
3-TBDMS morphine (155) dissolved in excess chloroform was stirred with 
10 equivalents by weight of activated manganese (IV) oxide for 15-20 minutes at 
about 38°C. Silica gel (Merck No. 7736, type 60H), (five equivalents by weight) 
was then added and stirring continued for 3-4 hours at the same temperature until the 
reaction was complete. The mixture was filtered through a thin pad of silica gel and 
evaporation of the filtrate gave almost pure 3-TBDMS-14-hydroxymorphinone 
(166) which can further be purified by flash chromatography, or crystallisation from 
ethyl acetate. By this method a 60% yield of the desired compound was obtained. 
We consider this to be satisfactory since all other options seem to involve many 
more steps and so far none had actually worked for us.
Reduction of 3-TBDMS-14-hydroxymorphinone
Hydrogenation of 3-TBDMS-14-hydroxymorphinone (166) to the 
coiresponding 7,8-dihydro derivative (169) took place without problems. The silyl 
hycroxymorphinone (166) was dissolved in absolute ethanol containing catalytic 
amounts of Pd/C (10%) and stirred under hydrogen for 2 hours to give the 
hycrogenated product in quantitative yield.







The expected molecular ion peak of the compound occurred at mlz 415 
together with the base peak at mjz 358 corresponding to the ion formed by the loss 
of r-butyl group from the molecule. In the n.m.r. spectrum the resonances of 7-H2 
and 8-H2 are seen as multiplets centred at 5 1.67 and 2.60.
14-Hydroxyl Protection
It remained to N-demethylate 7,8-dihydroxy-14-hydroxy-3-(TBDMS)- 
morphinone (169). Prior to this we considered that protection of the 14-hydroxyl 
group might be necessary. Since O-silyl units are easily removed, an obvious choice 
for protection is the TBDMS group which we have already shown to withstand 
N-demethylation conditions using chloroformates.
The 14-hydroxy group is tertiary and sterically crowded thus, we were not 
surprised to find that O-silylation proved difficult. No reaction occurred between the 
dihydromorphinone (169) dissolved in DMF and TBDMS chloride in presence of 
imidazole.
Barton and Tully156 report that TBDMS perchlorate is a more effective 
reagent which can be used in difficult cases. However, when this compound was
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reacted with the dihydromorphinone (169) in acetonitrile containing pyridine, only 
starting material was recovered. Another failure was experienced in a similar 
reaction, this time with TBDMS triflate157 and 2,6-lutidine.
A smaller silyl unit might be inserted, but these are normally less stable than 
TBDMS. In view of this we turned to O-acetylation. This was achieved without 
difficulty by heating the dihydromorphinone with acetic anhydride at reflux for 1 
hour. The acetoxy derivative (170) was thus obtained as a crystalline solid which in 
its infra red spectrum showed carbonyl bands as well as an ester band at 1735cm'1. 
In the n.m.r. spectrum the acetoxy methyl protons resonate as a singlet at 6 2.32.
Demethylation of 3-TBDMS-14-acetoxydihydromorphinone
The acetoxymorphinone (170) was treated in boiling dichloroethane with 
excess vinyl chloroformate for 3 days. Removal of solvent and excess reagent 
afforded 14-acetoxy-3-(TBDMS)-N-vinyloxycarbonyldihydronormorphinone (171) 
in 98% yield. It is a white powder which can be purified by column 
chromatography. The presence of the vinyl function in this compound is 
recognisable from the presence of an AMX spin-spin system in the n.m.r. 
spectrum with 1H multiplets at 5 4.81, 5.51 and 7.2. Significantly the chemical shift 






(170), R! = TBDMS, R2 = Ac, R3 = Me
(171), Ri = TBDMS, R2 = Ac, R3 = C 02CH=CH2
(174),R1=R3 =H ,R 2 = A c
(106), R! = R2 = R3 = H
Despite the long reaction time and the requirement for a large excess of 
reagent (10 molar equivalents) the productivity of the process is excellent. 
Interestingly, Kwiatkowski158 has claimed that 6-acetylcodeine (172) is 
N-demethylated by 5 equivalents of vinyl chloroformate simply by stirring the 
mixture in dichloromethane at room temperature for 2 days. The reported yield of 
N-vinyloxycarbonylnorcodeine (173) was 82%. When these conditions were applied 





(172), Rt = Ac, R2 = Me
(173), R! = Ac, R2 = C02CH=CH2
The carbamate (171) was dissolved in dichloromethane and the solution was 
saturated with hydrogen chloride. Evaporation of the solvent gave a hydrochloride 
salt which when warmed with methanol afforded 14-acetoxydihydronormorphinone 
(174) in 96% yield.
An alternative procedure is to reflux a solution of the carbamate in methanol 
containing a few drops of concentrated hydrochloric acid. This gave the same 
product in 98% yield. We also tried Kwiatkowski’s method for the 
decarbamoylation of similar compounds by stirring the carbamate (173) with a 
mixture of glacial acetic acid and concentrated hydrochloric acid. This reaction also 
failed.
Noroxymorphone
Finally 14-acetyl noroxymorphone (174) was heated with 6M hydrochloric 
acid under a nitrogen atmosphere at 100°C for 5 hours. The reaction mixture was 
then chilled and basified (pH = 9) with ammonia to precipitate noroxymorphone 
(106) as a dark coloured precipitate. This was collected by centrifugation, dissolved 
in dilute hydrochloric acid and reprecipitated with ammonia. The product is a
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colourless solid which was obtained in 88% yield.
Noroxymorphone (106) was characterised as its hydrochloride salt and 
compared with an authentic sample. Full details of the spectroscopic data are 
recorded in the experimental section.
Overall, the new synthesis requires seven steps and the yield is 45%. This 
represents a considerable improvement on existing routes particularly in brevity and 
economy. It is currently being evaluated on a larger scale by MacFarlan Smith Ltd..
Hydromorphone
As an extension to this work we were advised that hydromorphone 
(dihydromorphinone) (93) is a more potent analgesic than morphine (3-4 times as 
effective). MacFarlan Smith were interested in the preparation of this drug. We were 
able to prepare this compound easily from 3-(TBDMS) morphinone (165) by 
reduction and desilyladon (Scheme 38).
In this approach step one can be effected by hydrogenation at atmospheric 
pressure in ethanol over 10% palladium on carbon. The yield was 92%. The 
deprotection, step 2, is carried out by treating the dihydro derivative with tetrabutyl 














Overall hydromorphone can now be synthesized in four steps from morphine 
in 75% yield.
Previously the commercial route started from codeine (4) which is first 
oxidised to codeinone (40) and then hydrogenated to dihydrocodeinone (92). This 
product is O-demethylated by heating with hydrogen bromide to give 



















Melting points were recorded on an Electrothermal Mark II apparatus and were 
uncorrected. Infrared spectra are recorded on Perkin-Elmer 197 or 1310 grating 
spectrophotometers. *H n.m.r. spectra were run at 60 MHz on Perkin-Elmer R24B 
and Varian EM360 spectrophotometers; at 270 MHz on a JEOL JNM Fourier 
Transform spectrometer. 13C n.m.r. spectra were recorded at 67.8 MHz on a JEOL 
JNM Fourier Transform spectrometer. Chemical shifts are expressed in parts per 
million downfield from trimethylsilane (TMS) as internal standard. Mass spectra 
and high resolution accurate mass measurements were determined on a VG 7070E 
instrument with a VG 2000 data system. TLC analysis was performed on Merck 
DC-Alufolien plates coated with Kieselgel 60 F 254* Visualisation of reaction 
components was by u.v. light. Column chromatography was performed in short path 
columns packed with Merck 7736 Kieselgel and the solvent was eluted under 
pressure provided by hand bellows. Dry column chromatography was performed in 
cylindrical sinters packed with Merck 7736 Kieselgel and the solvent was eluted 
under water pump vacuum. Evaporations were carried out under water pump 
vacuum unless otherwise stated. Ethyl acetate, dichloromethane and pet. ether used 
for chromatography were distilled prior to use. The term pet. ether refers to light 
petroleum ether boiling at 60 - 80°C.
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Reagents
Tetrahydrofuran was dried by distillation from sodium/ benzophenone ketyl. 
Diethyl ether and benzene were dried by standing over sodium wire for at least one 
day. Dichloromethane was dried by distillation from calcium hydride. Methanol and 
ethanol were dried by distillation from magnesium turnings. Dimethylformamide 
was dried by standing over activated 4A molecular sieves. Molecular sieves were 
activated by heating to at least 150°C overnight. Unless otherwise stated all other 
solvents and reagents were used as supplied.
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4.2 Experimental to Chapter 1.
The powdered bark of Mimosa tenuiflora (100 g) was defatted by repeated 
extraction with petroleum ether ( 60 - 80°C ), ( 4 x 1/ ) at reflux. The defatted 
material was then extracted with boiling methanol ( 4 x 1.5/). The methanol extract 
on evaporation under reduced pressure gave a brown solid ( Solid 1, 42g ). The 
residue was then extracted with boiling water ( 3 x 1 / )  and the extract was 
evaporated under reduced pressure to give a light brown solid ( Solid 4, ca 12g ). 
‘Solid I* was partitioned between 2M hydrochloric acid and chloroform (200 cm3) 
and the mixture was extracted with dilute hydrochloric acid (4 x 50 cm3). The 
organic phase together with the insolubles was evaporated to get ‘Solid 2* (11.5 g). 
The acid extracts were combined and basified with concentrated NH3. An off-white 
solid was precipitated, this was not separated. Instead, the mixture was extracted 
with chloroform ( 5 x 100cm3 ) until the chloroform extract no longer gave a 
positive alkaloid test. The aqueous mixture was filtered to collect the chloroform 
insoluble basic material which was then dried ( Solid 3, 14g ). The chloroform 
extract was evaporated under reduced pressure to give the crude alkaloid. This was 
column chromatographed on silica using a chloroform - ethyl acetate - methanol 
mixture as the eluent. The fractions which contained the alkaloid were combined, 
evaporated and again purified by flash column chromatography on silica. 
Evaporation of the solvent gave a sample of the alkaloid which was then crystallised 
from ethyl acetate to give colourless crystals of WZ-dimethyltryptamine (0.42 g). Rf 
= 0.34 ( CHCI3 : EtOAc : MeOH = 4:5:6); m.p. = 48 - 49°C ( lit.3, 48 - 49°C); vmax 
(NaCl) 3220, 1560, 1250, 1100, 1000, 960 cm 1; 5h (CDC13) 2.35 ( 6H, s, N M ^  ),
2.65 ( 2H, t, /  = 7Hz, N-GH2-CH2- ), 2.96 ( 2H, t, /  = 7Hz, N-CH2-CH2- ), 6.99 ( 
1H, s, 2-H ), 7.08 - 7.63 ( 4H, m, 4-H, 5-H, 6-H, 7-H ), 8.16 ( 1H, br.s, indolic N-H 
); 813C (CDCI3) 23.68 ( -CH2-CH2-N ), 45.44 ( N-(CH3)2 ), 60.33 (-CH2-CH2-N), 
111.1, 118.8, 119.2, 121.4, 121.9 ( 5 indolic C-H ) 126.9, 132.0, 136.4 ( 3 indolic
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tart-C ); m/z (E.I.) 58 ( 100%, [C I^N M ^r ), 188 ( 40, M+ ), 144 ( 35, [M — 
N M eJ*); mlz (Cl.) 189 (100%, [M + H]+ ).
Carbohydrate Analysis
A methar.olic solution of ‘Solid 1* (20 mg/cm3 methanol) and solutions of glucose, 
fructose, galactose, xylose, maltose, glucuronic acid, ribose, mannose, raffinose and 
sucrose ( 10mg/cm3 of methanol) were prepared. These solutions were spotted on to 
TLC plates (silica) and developed using the following solvent systems.
Solvent 1: w-butanol-acetic acid-diethyl ether-water (9:6:3:1)
Solvent 2 : ethyl acetate-acetic acid-water (6:3:2)
Solvent 3 : /i-butanol-acetone-water (4:5:1)
The developed plates were dried in air and sprayed with p-aminobenzoic acid 
reagent*, dried and heated at 110°C for a few minutes. Rf values were noted and 
compared with those of reference compounds. Thus glucose and fructose were 
identified.
Solvent 1 Solvent 2 Solvent 3
Rf : Glucose 0.48 0.46 0.62
Rf : Fructose 0.42 0.57 0.64
Table 1.2
* p-Aminobenzoic acid reagent: p-aminobenzoic acid (3g) was dissolved in hot 
phosphoric acid (5cm3) and the solution was added to 300 cm3 of a mixture of 
/i-butanol, acetone and water (10:5:2).
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4.3 Minor Alkaloids of Opium
FRACTION 10
‘Fraction 10* a dark coloured, viscous liquid (100 g) was treated with dilute 
sulphuric acid ( 2M, 200 cm3 ) and the mixture extracted with chloroform ( 3 x 200 
cm3 ). The combined dry chloroform extracts on evaporation gave a residue (56 g) 
which contained no alkaloids. The aqueous layer was made alkaline with 
concentrated ammonia and extracted with chloroform ( 6 x 100 cm3 ). The 
chloroform extracts were combined, dried ( Na2S04 ) and evaporated under reduced 
pressure to give a dark brown residue. This was dissolved in methanol and 
evaporated with silica ( ca lOg ), the material obtained was added to the top of a 
column of silica and chromatographed using petroleum ether - ethyl acetate mixtures 
as the eluent The fractions obtained were grouped by TLC analysis and evaporated 
individually and rechromatographed. Each compound obtained from the column was 
further purified by crystallisation or flash column chromatography. The analytical 
data of the identified compounds is given below and the yields and Rf values in 
Table 1.
Analytical data
Bis [ 4-( NJV - dimethylamino ) phenyl ] methane (134)
M.p. 90 - 92°C, ( lit.,126 91°C); \)max: 3010, 1600,1500,1445,1360, 1220 and 1050 
c m 1; 5„ ( CDC13 ) 2.89 ( 12H, s, 4 x N-CH3 ), 3.80 ( 2H, s, CH2 ), 6.67 - 7.02 ( 8H, 
dd, /  = 8.8 Hz, 8 x Ar-H ); 5c ( CDC13 ) 39.9 ( CH2 ), 40.9 ( N-CH3 ), 113.4 ( Ar-C 
), 128.1 ( Ar tert -C ), 129.4 ( Ar-C); mlz ( E .I.) 134 (100% ) ,  253 (32), 254 ( 30,
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M+ ); ( C .I.) 254 ( 100, M+ ), 255 (78), 134 (75). ( Found M: 254.1754, calculated 
for C17H22N2 : 254.1783)
Noscapine (2)
M.p. 174 - 176°C ( EtOAc ), ( /ft.,159 176°C ); Rf = 0.75 ( CHC13 : MeOH : NH3 = 
90 : 10 : 1 ); 3500, 2860, 1750, 1708, 1610, 1445, 1370, 1263, 1203, 1180,
1120, 1050, 1010, 972, 860, 810 and 782 cm 1; 8„ ( CDC13 ) 1.91 - 2.61 ( 4H, m, 
N-CH2-CH2- ), 2.55 ( 3H, s, N-CH-,), 3.86,4.04 and 4.09 (3  x 3H, 3 x s, 3 x 0-CH3 
), 4.40 ( 1H, d, J  = 4.0 Hz, 1-H ), 5.58 ( 1H, d, /  = 4.0 Hz, 9-H ), 5.94 ( 2H, s,
0-CH2- 0 ), 6.08 ( 1H, d, /  = 8.25 Hz, 5’-H ), 6.31 ( 1H, s, 5-H ), 6.96 ( 1H, d , /  = 
8.25 Hz, 6’-H ); mil ( E .I.) 220 ( 100% );( C .I.) 220 (100), 414 (95, M++l ), 412 
(20).
Papaverine (3)
M.p. 147 - 148°C ( lit.,160 147 -148°C); Rf = 0.64 ( CHC13 : MeOH: NH3 = 90 : 10 
: 1); v ma 3400 - 3100 br, 2900,2820, 1585,1560,1490,1450,1410, 1342, 1250 - 
1180 (br.), 1142, 1130, 1020,980, 880, 850 cm 1; 6h ( CDC13 ) 3.77, 3.82, 3.91 and
4.0 (4  x 3H, 4 x s, 4 x OCH3 ), 4.54 ( 2H, s, -CH2- ), 6.74 - 6.83 ( 3H, m, 2’-H, 5’-H 
and 6’-H ), 7.05 ( 1H, s, 8-H ), 7.35 ( 1H, s, 5-H ), 7.43 ( 1H, d, J3A « 5.7 Hz, 4-H ), 
8.37 ( 1H, d, /  = 5.7 Hz, 3-H ); mlz ( E . l . ) 338 ( 100%, M - 1 ), 324 ( 98, M - CH3 
), 339 ( 63, M+ ); ( C .l .) 340 (100, M + 1).
Thebaine (5)
M.p. 190 - 192°C ( EtOH ), ( lit.,161 193°C ); \)mK 2895, 2820, 1597, 1490, 1300,
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1163, 1140,1100, 1029,1010, 970,910 and 860 cm'1; 5h ( CDC13 ) :  1.7 - 2.2 ( 2H, 
m, 15-H2 ), 2.48 ( 3H, s, N-CH3 ), 2.70 ( 1H, dd, Jgem = 18.2 and J9AQ = 7.0 Hz, 
1 0 - ^  ), 2.7 - 2.9 ( 2H, m, 16-H2 ). 3.33 ( 1H, d, /  = 18.1 Hz, 10-Hp ), 3.61 ( 3H, s, 
6-OCH3 ), 3.69 ( 1H, d, J9tl0 = 7.0 Hz, 9-H ), 3.85 ( 3H, s, 3-0-CH3 ), 5.07 ( 1H, d, J  
= 6.5 Hz, 8-H ), 5.28 ( 1H, s, 5-H), 5.56 ( 1H, d, /  = 6.4 Hz, 7-H ), 6.50 - 6.66 ( 2H, 
dd, J  -  8.0 Hz, 1-H and 2-H) ;  m/z ( E .l .), 311 (100%, M+), 255 (40).
Codeine (4)
M.p. 155 - 156°C ( l i t ,162 156 - 157°C ); \)max 3540, 1640, 1616, 1510, 1330, 1320, 
1280,1250,1230,1180,1152,1140,1105,1080,1060,1030,980,949, 890, 865 and 
830 cm 1; 5h ( CDC13 ) 1.88 ( 1H, dm, / gem = 12.8 Hz, 15-Ha), 2.06 ( 1H, td, / gem = 
12.8 and / 1516 = 5.1 Hz, 15-Hp ), 2.30 ( 1H, dd, / gem = 18.7 and / 10,9 = 6.2 Hz, 
10-Ha ), 2.36 ( 1H, dd, Jgem = 12.6 and / 16?15 = 5.6 Hz, 16-Ha ), 2.44 ( 3H, s, 
N-CH3 ), 2.59 ( 1H, dm, /  = 12.5 Hz, 16-Hp ), 2.67 ( 1H, m, 14-H ), 2.9 ( 1H, br.s, 
6-OH ), 3.05 ( 1H, d, Jgem = 18.6 Hz, 10-Hp ), 3.35 ( 1H, dd, V9>10 = 5.9 and J9M = 
3.3Hz, 9-H ), 3.84 ( 3H, s, 0-CH3 ), 4.18 ( 1H, m, 6-H ), 4.90 ( 1H, d, J5 6 = 6.6 Hz,
5-H ), 5.30 ( 1H, dt, J8J = 9.9 Hz and / 814 = 2.6 Hz, 8-H ), 5.71 ( 1H, dm, J1S = 9.9 
Hz, 7-H ), 6.56 - 6.68 ( 2H, dd, AB system, /  = 8.2 Hz, 1-H and 2-H ); m/z ( E . l . ) 
299 ( 100%, M+ ); ( C .l .) 282 ( 100, M - OH), 299 ( 80, M+), 300 (70, M + l).
FRACTION 4
Traction 4’ is a dark coloured sticky solid insoluble in water, but soluble in 
methanol. A methanolic solution of a sample of ‘fraction 4’ (4.0 g) was prepared and 
evaporated with silica (10 g). This was added to the top of a column of silica and 
chromatographed with petroleum ether ( 40 - 60°C ) - chloroform mixture as eluant 
first and then with chloroform - methanol mixture, progressively increasing the
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polarity of each solvent mixture. Fractions (25 cm3) were collected and analysed by 
TLC on silica with chloroform - acetone - methanol - ammonia (25 : 20 : 5 :1) 
mixture as eluant The first twenty-five fractions contained no alkaloid, but 
evaporation and purification gave a colourless liquid which was identified as 2-(
4-hydroxyphenyl) ethanol (135), ( 6 mg, 0.15% ). The next few fractions contained 
two alkaloids and these fractions were combined and the alkaloids separated by 
flash column chromatography on silica with petroleum ether - ethyl acetate solvent 
mixture. The alkaloids were identified as noscapine (2), ( 120 mg, 3% ) and 
papaverine (3) ( 64 mg, 1.6% ). In similar manner the remaining components were 
separated and purified by flash column chromatography and identified as thebaine
(5), (1 2  mg, 0.3% ), narcotoline (136), ( 8 mg, 0.2% ), palaudine (137), ( 56 mg, 
1.4% ), oripavine (138), ( 10 mg, 0.25% ), codeine (4), ( 20 mg, 0.5% ) and 
morphine (1), (12 mg, 0.3% ). Noscapine, papaverine, thebaine and codeine were 
identified by comparing their spectral data with those of the samples previously 
characterised (p. 124 -125).
Analytical data
2-(4-Hydroxphenyl)ethanol (134)
8h ( CDC13 ) 1.59 ( 1H, br.s, -CH2OH ), 2.81 ( 2H, t, /  = 6.6 Hz, CH2-CH2OH ), 
3.83 ( 2H, t, /  = 6.4 Hz, CH2-CH2OH ), 4.84 ( 1H, s, phenolic-OH ), 6.78 ( 2H, d, J  
= 8.6 Hz, 2 x Ar-H), 7.1 ( 2H, d, /  = 8.4 Hz, 2 x Ar-H); mfr ( E.I. ) 107 (100%, M - 
CH2O H ), 138 (22, M+); ( C .I.) 121 (100, M - O H ), 107 (60), 138 (40).
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Narcotoline (136)
M.p. 200 - 202°C ( lit.,163 202°C); Rf = 0.64 ( C H d3 : CH3COCH3 : CH3OH : NH3 
= 25 : 20 : 5 : 1 ); 3250, 2900, 1740, 1620, 1470, 1365, 1250, 1190, 1065,
1000, 895,840,805,755,710,650 and 620 cm 1; 8h ( CDC13 ) 1.95 - 2.70 ( 4H, m, 
N-CH2-CH2- ), 2.54 ( 3H, s, N-CH3 ), 3.87 and 4.10 ( 2 x 3 H , 2 x s , 2 x  0-CH3 ), 
4.40 ( 1H, d, /  = 4.4 Hz, 1-H), 5.66 ( 1H, d, 7 = 4.2 Hz, 9-H ), 5.97 ( 2H, q, 7 =
1.1 Hz, 0-CH2-0), 6.21 ( 1H, d , /  = 8.1,2’-H ), 6.3 ( 1H, s, 5-H ), 6.98 ( 1H, d, 
J  = 8.4 Hz, 3’-H ); m/z (%) : ( EX ) 206 (100), 399 ( 5, M+ ); ( C .I.) 206 (100), 400 
(7, [M+H]+).
Palaudine (137)
Rf = 0.61 ( CHCI3 : CH3COCH3 : CH3OH : NH3 = 25 :20 : 5 : 1 ); m.p. = 174 - 
175°C ( lit.,164 175 - 176°C ); v ^ c m 1 : 3430, 300, 2870, 1620, 1590,1480, 1463, 
1450, 1385,1350, 1273,1235,1200,1080,1050,1030,960, 860, 824; 8h ( CDC13 ) 
3.82,3.89 and 4.00 (3  x 3H, 3 x s, 3 x OCH3 ), 4.49 ( 2H, s, -CH2- ), 6.5 ( 1H, br.s, 
3’-O H ), 6.75 - 6.81 ( 3H, m, 2’-H, 5’-H, 6’-H ), 7.03 ( 1H, s, 5-H /  8-H ), 7.32 ( 1H, 
s, 5-H /  8-H ), 7.39 ( 1H, d, /  = 5.7 Hz, 4-H ), 8.29 ( 1H, d, /  = 5.7 Hz, 3-H ); m/z 
(%): ( E .l.) 324 ( 40, [M-H]+), 325 ( 25, M+); ( C .I) 326 (100, [M+H]+ ), 325 ( 40, 
M+ ).
Oripavine (138)
Rf = 0.58 ( CHCI3 : MeCOMe : MeOH : NH3= 25 : 20 : 5 :1 ); m.p. = 198 - 199°C 
(lit,165 201 - 202°C ); vmaxcm * 3520, 3200 (br.), 2895, 2820, 1597, 1440, 1360, 
1320, 1300,1130, 1100,1010,970,910, 860; 8h ( CDC13 ) 1.74 ( 1H, d d ,/=  12.5 
and 2.1 Hz, 15-Hfj), 2.24 ( 1H, td, /  = 12.5,5.1 Hz, 15-Hp), 2.48 ( 3H, s, N-CH3 ),
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2 .70 ( 1H, dd, /  = 18.2 and 7.0 Hz, 10-Ha), 2.65 - 2.70 ( 1H, m, 16-Ha ), 2.90 ( 1H, 
td, /  = 12.8 and 3.5 Hz, 16-Hp ), 3.33 ( 1H, d, /  = 18.0Hz, 10-Hp ), 3.61 ( 3H, s, 
6-OCH3 ), 3.69 ( 1H, d, /  = 7.0Hz, 9-H ), 5.07 ( 1H, d, /  = 6.6 Hz, 8-H ), 5.30 ( 1H, 
s, 5-H ), 5.58 ( 1H, d, /  = 6.4 Hz, 7-H ), 6.53 - 6.66 ( 2H, dd, /  = 8.1 Hz, Ar 1-H and 
2-H ); m/z (%) 57 (100), 148 (80), 297 (55, M+); ( low E.VJE.I.) 297 (100, M+).
Morphine (1)
Rf = 0.22 ( CHCI3 : MeCOMe : MeOH : NH3 = 25 : 20 : 5 : 1 ), m.p. = 250 - 253°C 
(lit.,166, 253 - 254°C ); v ^ c m '1 : 3460, 3310, 3120, 2300,1590, 1300, 1230, 1110, 
1075, 1010, 930, 820, 790, 750; ^  ( CD3OD ): 1.70 - 2.10 ( 2H, m, 15-H2 ), 2.29 
(1H, dd, /  = 18.8 and 6.4 Hz, 10-Ha ), 2.37 ( 3H, s, NCH3 ), 2.40 - 2.55 ( 2H, m, 
16-H2 ), 2.59 ( 1H, m, 14-H ), 2.96 ( 1H, d, / gem = 18.9 Hz, 10-Hp ), 3.07 ( 1H, br.s, 
6-OH ), 3.32 ( 1H, q, / 9fl0 = 6.4 Hz and J9M = 3.3 Hz, 9-H ), 4.12 ( 1H, m, 6-H ), 
4.75 ( 1H, d, / 56 = 6.2 Hz, 5-H ), 5.24 ( 1H, ddd, J  = 9.9,2.8 and 2.6 Hz, 8-H ), 5.56 
( 1H, dm, J  = 9.9 Hz, 7-H ), 6.40 - 6.60 ( 2H, dd, /  = 8.1 Hz, 1-H and 2-H ); m/z (%): 
( E.L ) 285 (100, M+ ), 162 (40), 215 (30).
FRACTION 7
A sample of ‘fraction 7* (3.0 g) was column chromatographed on silica using 
chloroform - methanol solvent system and the alkaloids isolated were purified 
further by flash column chromatography or by crystallisation ( as described in the 
case of ‘fraction 4* ). Five alkaloids were identified from this fraction. They are 
noscapine (2), papavarine (3), codeine (4), laudanosine (140) and xanthaline (139). 
Noscapine (2), papaverine (3) and codeine (4) were identified by IR, NMR and MS 




Rf = 0.59 ( CHCI3 : CH3OH : NH3 = 90 :10 : 1); m.p. = 87 - 89°C ( l i t ,168 89°C); 
v ^ ,  cm 1: 2890,2820,1585, 1495, 1430,1330, 1315, 1230-1180 (br.), 1120, 1090, 
1000,850; 5|{ ( CDC13 ) :  2.48 - 2.88 ( 4H, m, N-CH2-CH2- ), 2.55 ( 3H, s, NCH3 ), 
3.18 ( 2H, m, CH2 ), 3.69 ( 1H, q, /  = 5.1 and 2.6 Hz, 1-H ), 3.56, 3.79, 3.84 and 
3.85 (4  x 3H, 4 x s, 4 x OCH3 ), 6.05 ( 1H, s, 5-H ), 6.56 ( 1H, s, 8-H ), 6.60 - 6.78 
(3H, m, 2’-H, 5’-H, 6’-H ); m/z (%): ( E .l.) 206 (100), 207 (20); ( C .I.) 206 (100), 
358 (30, [M+H]+ ).
Xanthaline (139)
Rf = 0.79 ( CHC13 : CH3OH : NH3 = 90 : 10 : 1). m.p. = 207 - 209°C ( lit.,167 208 - 
209°C ); vm„  cm'1: 2920, 2820, 1640, 1615, 1578, 1490, 1455, 1400, 1335, 
1260-1180 (br), 1130, 1010,935, 875, 850; 8„  ( CDC13 ) :  3.95, 3.96, 3.97,4.06 (4  
x 3H, 4 x s, 4 x OCH3 ), 6.87 ( 1H, d, Jy<6- = 8.4 Hz, 5’-H ), 7.12 ( 1H, d, JYfi- = 1.8 
Hz, 2’-H ), 7.15 ( 1H, s, 5-H ), 7.42 ( 1H, dd, J6-s  = 8.4 Hz, J6-x  = 1.8 Hz, 6’-H ),
7.55 ( 1H, s, 8-H ), 7.66 ( 1H, d, / 4>3 = 5.5 Hz, 4-H ), 8.46 ( 1H, d, J3A = 5.7 Hz, 3-H 
); m/z ( E .l.) 353 ( 100, M+ ), 324 (80), 165 (80); ( C .I.) 354 ( 100, [M+H]+ ), 353 
(40, M+)
FRACTION 13
‘Fraction 13’ is a black spongy solid, insoluble in organic solvents but soluble in 
water. A sample (12 g) of the material was dissolved in water, acidified with dilute 
H2S04 and extracted with diethyl ether. Ether extract on evaporation gave no
residue. Aqueous layer was basified with concentrated NH3 and extracted first with 
diethyl ether ( 6 x 50 cm3 ) and then with chloroform ( 6 x 50 cm3 ). The ether 
extract was dried, concentrated and kept in a fridge overnight when colourless 
crystals of a substance were formed. This was recrystallised from methanol and 
identified as cryptopine (142) ( 0.245 g, 2.5% ). The chloroform extract was 
evaporated and the compounds in the residue were isolated by short column 
chromatography ( silica, petroleum ether - ethyl acetate first and then ethyl acetate - 
methanol mixture as eluant ). The fractions were evaporated and purified. The 
alkaloids identified are noscapine (2), ( 0.062 g, 0.5% ), papaverine (3) (0.21 g , 
1.8% ), laudanosine (140), ( 0.033 g, 0.3% ), thebaine (5) ( 0.03 g, 0.25% ) and 
codeine (4), (0.249 g, 2% ).
Analytical data
Cryptopine (142)
Rf = 0.57 ( CHC13 : CH3OH : NH3 = 90 : 10 : 1) m.p. = 220 - 221°C ( lit.,169 223°C 
); vmax cm'1 3510 - 3400 (br.) 2860, 2820, 1640, 1592, 5485, 1440, 1335, 1180 - 
1240 (br.), 1110, 1030 (br), 970, 930, 850; ^  ( CDC13 ): 1.6 - 2.6 ( 4H, m, 5-CH2-,
6-CH2- ), 3.55 - 3.65 ( 4H, m, 8-CHr , 13-CH2- ), 3.89 ( 3H, s, OCH3 ), 3.90 ( 3H, s, 
OCH3 ), 5.94 ( 2H, s, 0-CH2-0  ), 6.70 ( 1H, s, 4-H ), 7.00 ( 1H, s, 1-H ); m/z (%): 
(E.I.) 148 (100), 369 ( 5, M+); ( C.I.) 148 (100), 370 ( 82, [M+H]+ ).
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4.4 N-Demet hy la t ion of Oxycodone
14- Acetyloxycodone (143)
Oxycodone (104), (3.15 g, 10 mmol) was heated under reflux with acetic anhydride 
(15 cm3) for 1 hour. The mixture was then cooled, poured into ice (60g) and stirred 
to room temperature to hydrolyse the excess anhydride. It was again cooled to 0°C 
and basified with concentrated ammonia to pH 9. A white precipitate of 
14-acetyloxycodone (143) was formed and this was collected by Alteration, washed 
with water and dried in the vacuum oven at 65°C. Yield = 3.55 g (quantitative). It 
was crystallised from 95% ethanol. Rf = 0.5 ( CH2Cl2 : CH3OH = 9 : 1 ) ;  m.p. 206 - 
208°C ( lit.,109 206 - 210°C); vmax 3520,1720, 1630,1600,1430,1360,1310, 1150, 
1098, 1010, 950 and 880 cm 1; ^  ( CDC13 ), ( 400 mHz ), 1.54 ( 1H, dm, /  = 11.9 
Hz, 8-Ha ), 1.64 ( 1H, ddd, J  = 14.6 and 3.7 Hz, 15-Ha ), 2.19 ( 3H, s, N-CH3 ), 
2.16 - 2.20 ( 1H, m, /  = 11.6 Hz, 8-Hp ), 2.28 ( 1H, dt, J  = 14.9 and 3 Hz, 15-Hp ), 
2.32 ( 3H, s, -COCH3 ), 2.45 ( 1H, m, /  = 12.2 and 5.5 Hz, 7-Ha ), 2.5 ( 1H, dd, /  =
18.3 and 5.2 Hz, 10-Ha )» 2 54 ( 1H> 7 = 12 2 5  2 ^  7"HP )> 264 ( 1H» J
= 14.6 and 5.2 Hz, 16-Ha ), 2.81 ( 1H, ddd, /  = 14.3, 5.2 and 2.75 Hz,16-Hp ), 3.21 
(1H, d, J  = 18.6 Hz, 10-Hp ), 3.89 ( 3H, s, 0-CH3 ), 4.19 ( 1H, d, /  = 5.5 Hz, 9-H ), 
4.67 ( 1H, s, 5-H), 6.64 - 6.72 ( 2H, dd, AB system, J  = 8.0 Hz, 1-H and 2-H); 5C ( 
CDC13 ) : 22.2 ( CH3CO ), 22.3 (C-8), 27.0 (C-7), 29.9 (C-10), 35.5 (C-15), 42.6 ( 
CH3-N ), 45.6 (C-16), 56.8 ( CH30  ), 57.8 (C-9), 76.5 (C-13), 77.0 (C-14), 77.5 
(C-ll), 82.4 (C-12), 89.9 (C-5), 115.2 (C-l), 119.5 (C-2), 143.0 (C-3), 146.0 (C-4), 
162.0 (C-6), 170.0 ( OOCH3 ); m!z (%) : ( E.l. ) 357 ( 100, M+ ), 314 ( 45, M - 
CH3CO).
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N-( 1 -Chloroethoxycarbonyl )-14-acetylnoroxycodone (148)
1-Chloroethyl chloroformate (1.4 cm3; 1.85 g, 13 mmol) was added slowly to a 
cold solution of 14-acetyloxycodone (143), (1.4 g, 3.8 mmol) in 1,2-dichloroethane 
(12 cm3) at 0°C. The mixture was then heated at 65°C under nitrogen for 20 hours 
and then at reflux for 2 hours. The volatiles were removed under reduced pressure to 
give a colourless solid which was flash chromatographed on silica with chloroform 
as eluant to give N-( 1-chloroethoxycarbonyl)- 14-acetylnoroxycodone (148), ( 1.25 
g, 71% ). Rf = 0.78 ( CH2C12 : CH3OH = 9 : 1 ) ;  vmax: 1745, 1715, 1630, 1605 and 
1513 cm 1; 5„ ( CDC13 ) : 1.85 ( 3H, d, /  = 5.9 Hz, -OTCl-CH, ), 2.18 ( 3H, s, 
CO-CH3 ), 3.90 ( 3H, s, OCH3 ), 6.40 - 6.90 ( 3H, m, 1-H, 2-H and -CHC1-CH3 ).
Deprotection o f N-carbamate and 14-acetyl groups from N-(l-chloroethoxy- 
carbonyl)-14-acetylnoroxycodone (148)
A solution of N-( 1-chloroethoxycarbonyl )-14-acetylnoroxycodone (148), ( 1.2 g,
2.7 mmol) in methanol (20 cm3) was heated under reflux for 2 hours. The mixture 
was cooled and the solvent was evaporated to give 14-acetylnoroxycodone (149). 
This was dissolved in dilute hydrochloric acid ( 6M, 15 cm3 ) and heated at 100 - 
102°C for 5 hours. The mixture was cooled to 0°C, basified with concentrated 
ammonia to pH 8.5 and extracted with dichloromethane ( 10 x 10 cm3 ). The 
combined organic extracts were washed with water, dried ( Na2S04 ) and evaporated 
to yield noroxycodone (131), (0.78 g, 97% yield; 68.9% from 14-acetyloxycodone). 
The product which contains both secondary amine and ketone groups cannot be 
crystalised without decomposition as reported by Seki.171 M.p. 160 - 165°C 
foaming, then 306°C dec. ( lit.,171 160°C foamimg, then 310°C dec.); Rf = 0.065 ( 
CH2C12 : MeOH = 9 : 1 ) ;  vmax: 3350 - 3200 (br.), 1718 and 1598 cm'1; §h ( CDC13 )
1.56 - 3.19 ( 1H, m, 7-H2, 8-H2, 9-H, 10-H2, 15-H2, 16-H2 ), 3.90 ( 3H, s, OCH3 ),
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4.66 ( 1H, s, 5-H), 4.94 ( 1H, br.s, 14-OH), 6.62 - 6.73 ( 2H, dd, AB system, J  = 8.2 
Hz, 1-H and 2-H); mlz (%): ( E .l.) 301 (100, M+), 83 (63), 216 (45).
The preparation of noroxycodone from acetyl oxycodone was repeated without 
purifying the intermediate N-carbamate. The product obtained however was found 
to be a mixture of noroxycodone and oxycodone. Column chromatographic 
separation on silica gave 68% of noroxycodone as the best yield. About 23% of 
oxycodone was also recovered.
N-Demethylation with vinyl chloroformate
A mixture of 14-acetyloxycodone (143), ( 0.71 g, 2 mmol ) in 1,2-dichloroethane 
(20 cm3) and vinyl chloroformate ( 0.35 cm3; 0.43 g, 4 mmol) was heated at 50°C 
under nitrogen for 120 hrs. Further portions of vinyl chloroformate were added after 
72 hrs and 96 hrs ( 0.35 cm3 each ). The mixture was poured into saturated sodium 
hydrogen carbonate and extracted with dichloromethane. The extract was dried and 
evaporated to give N-vinyloxycarbonyl-14-acetylnoroxycodone (150). It was 
purified by column chromatography on silica eluting with chloroform - methanol 
(100 : 1) mixture to yield a colourless foam of the carbamate (150). This product 
was dissolved in dry dichloromethane (10 cm3) and hydrogen chloride gas was 
passed through the solution for one hour. The solvent was evaporated under reduced 
pressure, and the residue was heated under reflux with methanol for one hour. The 
solvent was evaporated under reduced pressure, the residue was mixed with 
saturated sodium hydrogen carbonate solution and extracted with dichloromethane, 
the extract was dried ( Na2S04 ) and evaporated to give 14-acetylnoroxycodone 
(149), ( 0.6 g, 88% ) as a glassy solid. The acetyl group was hydrolysed to give 
noroxycodone (131) as explained in the previous experiment.
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N-Demethylation with phenyl chloroformate
A mixture of 14-acetyloxycodone (143), ( 0.71 g, 2 mmol) dissolved in chloroform 
(50 cm3), sodium hydrogen carbonate ( 4.2 g, 50 mmol) and phenyl chloroformate 
(2.5 g, 15 mmol ) was refluxed with efficient stirring under nitrogen for 20 hours. 
The mixture was cooled, filtered and evaporated. Anhydrous hydrazine (5 cm3) was 
added slowly to the product, followed by 64% hydrazine (2 cm3) and the mixture 
was heated under reflux in the atmosphere of nitrogen for 24 hours. The mixture was 
cooled, water (20 cm3) was added and the water was removed in vacuo. The 
addition and removal of water was repeated twice more. Phenol was then removed 
from the mixture under high vacuum at 120°C. The residue was dissolved in a 
mixture of water (100 cm3) and chloroform (200 cm3), and the mixture was made 
alkaline with concentrated ammonia, and the chloroform layer was separated, 
washed with 10% KOH solution and, then with water, dried ( Na2S04 ) and 
evaporated to give 14-acetylnoroxycodone (149), ( 0.45 g, 66% ) which on 
purification by column chromatography on silica with chloroform - methanol ( 9:1 ) 
gave pure product (149), (0.38 g, 56% ).
N-Demethylation with 2,2,2-trichloroethyl chloroformate
A mixture of 14-acetyloxycodone (143) ( 0.71 g, 2 mmol ), anhydrous potassium 
carbonate (0.6 g, 4 mmol) and 2,2,2-trichloroethyl chloroformate (2.9 cm3; 4.26 
g, 20 m m ol) in chloroform (100 cm3) was refluxed under nitrogen for three days. 
The mixture was cooled, washed with water, dried ( Na2S04 ) and evaporated and 
the residue obtained was dissolved in glacial acetic acid (15 cm3) and stirred with 
zinc dust (1 g) at room temperature for 4 hours. The zinc dust was filtered off and 
the filtrate was basified with concentrated ammonia and extracted with chloroform. 
The chloroform extract on evaporation gave acetylnoroxycodone (149), which was
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purified by column chromatography on silica using chloroform-methanol (9:1 ) to 
elute. (0.14 g, 20.5% ).
N-Demethylation with ethyl chloroformate
A mixture of 14-acetyloxycodone (143) (0.71 g, 2 mmol), ethyl chloroformate (1.9 
cm3, 2.2 g, 20 mmol) and potassium carbonate ( 1 g, 7 mmol) in chloroform (100 
cm3) was heated under reflux for 8 hours. The mixture was cooled, washed with 
water, dried ( Na2S04 ) and evaporated to give a residue. This was dissolved in 
dilute sulphuric acid ( 5M, 10 cm3 ) and refluxed under nitrogen for 12 hours. The 
mixture was cooled, basified with solid sodium hydrogen carbonate and extracted 
with chloroform. Evaporation of the chloroform extract and column 
chromatographic separation of the residue gave noroxycodone (131), (0.10g, 
16.6%).
The experiment was repeated by heating the mixture of acetyl oxycodone, ethyl 
chloroformate and potassium carbonate in chloroform under nitrogen for one week. 
The reaction mixture was found to contain N-ethoxycarbonyl-14-acetylnor- 
oxycodone in similar yield (15 - 20% ).
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4.5 O-Demethylation of Oxycodone
O-Demethylation o f oxycodone with hydrogen bromide
Oxycodone (104), ( 0.60 g, 1.9 mmol ) was introduced into concentrated 
hydrobromic acid (10 cm3) at 90°C and the mixture was heated at 110 - 120°C for 1 
hour. The mixture was cooled, basified with concentrated sodium hydroxide to pH 
10-11 and extracted with chloroform to recover the unreacted oxycodone ( 0.1 g, 
17% ). The aqueous phase was chilled and made acidic with hydrochloric acid and 
then basic with concentrated ammonia to pH 8.5. The mixture was again extracted 
with chloroform, the chloroform extract was dried and evaporated to yield 
oxymorphone (105), ( 0.35 g, 61%, 73% based on the reacted oxycodone ). It was 
crystalised from ethanol to give colourless crystals. M.p. 244 - 247°C darkening 
(lit.,100 248 - 249°C, darkening ); Rf = 0.2 ( CH2C12 : MeOH, 9 : 1 ) ;  vmax 3340 (br.), 
1710, 1610 and 1300 cm 1; SH ( CDC13 ) 1.56 ( 1H, m, /  = 13.9 Hz, 15-Ha), 1.68 ( 
1H, dd, J  = 14.3 and 3.3 Hz, 8-Ha ), 1.9 ( 1H, m, 15-Hp ), 2.1 - 2.34 ( 3H, m, 7-H2 
and 8-Hp ), 2.42 ( 3H, s, NCH3 ), 2.44 ( 1H, m, 16-Ha ), 2.56 ( 1H, dd, /  = 18.7 Hz 
and 5.5 Hz, 10-Ha ), 2.9 ( 1H, d, J  = 5.9 Hz, 9-H ), 3.05 ( 1H, dd, J  = 14.2 Hz and
5.1 Hz, 16-Hp ), 3.16 ( 1H, d, /  = 18.7 Hz, 10-Hp ), 4.71 ( 1H, s, 5-H), 6.59 - 6.75 
(2H, dd, /  = 8.1 Hz, 1-H and 2-H); m!z ( low E.V.E.I.) 301 (100%, M+ ).
O-Demethylation with boron tribromide
A solution of oxycodone (104), (0.32 g, 1 mmol) dissolved in dichloromethane (30 
cm3) was treated with solution of BBr3 (1  cm3, 1M solution in dichloromethane, 10 
mmol ) in dichloromethane at -70°C under nitrogen. The mixture was allowed to 
warm to room temperature and continued stirring for one hour. Excess boron 
tribromide was destroyed by treating with methanol (2 cm3), the mixture was
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basified with 1% sodium hydroxide solution and extracted with chloroform to 
recover unreacted oxycodone. The aqueous phase was acidified with concentrated 
hydrochloric acid to pH 5 and then basified with concentrated ammonia to pH 9 and 
extracted with chloroform to yield oxymorphone (50), (0.15 g, 49% ).
Attempted O-demethylation with trimethylsilylchloride and sodium iodide
A mixture of oxycodone (104) ( 0.6 g, 1.9 mmol ), in dry acetonitrile (10 cm3), 
trimethylsilylchloride ( 0.4 cm3; 0.38 g, 3.5 mmol) and sodium iodide ( 0.5 g, 3.3 
mmol ) was stirred under nitrogen at 45°C for 60 hours. The mixture was diluted 
with water (10 cm3) and extracted with chloroform. The chloroform extract was 
analysed and found to contain only the starting material.
O-Demethylation with trimethylsilyliodide
Oxycodone ( 0.6 g, 1.9 mmol ) dissolved in carbon tetrachloride (20 cm3) was 
stirred with trimethylsilyliodide ( 0.6 g, 3 mmol ) under nitrogen at 50°C for two 
days. The mixture was then cooled and then shaken with 1% NaOH solution (25 
cm3) and extracted with chloroform. The organic extract on evaporation yielded a 
mixture of oxycodone with some unidentified product ( 0.24 g, approximately 
40%). The aqueous layer was acidified first with hydrochloric acid and then basified 
with concentrated NH3 to pH 8.5 - 9.0 and extracted with chloroform to yield 
oxymorphone (0.1 g, 17% ).
O-Demethylation with n-propanethiol
A solution of oxycodone (104), ( 1.1 g, 3.5 mmol) in dry DMF was degassed under 
nitrogen by stirring under vacuum followed by inletting nitrogen. Potassium
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rm-butoxide (1.10 g, 9.8 mmol) was added to the above solution and the degassing 
process was repeated and then n-propanethiol ( 1.2 cm3, 13 mmol) was introduced 
by a syringe. The mixture was heated at 110°C under nitrogen for 3 hours cooled 
and quenched with acetic acid (1 cm3). The solvent was removed under high 
vacuum and the residue was dissolved in dilute hydrochloric acid ( 1M, 20 cm3 ). 
The solution was washed with ether, treated with 20% sodium bisulphite solution (2 
cm3) and basified with concentrated ammonia to pH 9.0. The precipitate was 
collected by nitration (0.88 g) and was found to be a mixture of oxycodone ( Rf =
0.42, CH2C12 : CH3OH = 9 : 1 )  and oxymorphone (Rf = 0.20, same solvent system). 
The mixture was separated by flash column chromatography to yield oxycodone 
(104), (0.5 g) and oxymorphone (105), (0.11 g, ca 10% ).
Attempted O-demethylation of oxycodone with lithium diphenylphosphide
(i) Preparation of lithium diphenylphosphide
Lithium metal ( 0.14 g, 2 g atom ) was added to dry THF (10 cm3) and then 
chlorodiphenyl phosphine (1.1 cm3, 5 mmol) was added dropwise under nitrogen. 
The mixture was stirred under nitrogen at room temperature for 2 hours. A red 
solution of the lithium diphenylphosphide resulted was used for demethylation as 
follows.
(ii) Demethylation
Oxycodone (104), ( 0.8 g, 2.5 m mol) was added to the above solution of lithium 
diphenylphosphide under nitrogen and the mixture was stirred for 2 hours. It was 
poured into 10% hydrochloric acid (100 cm3) and extracted with ether (4 x 50 cm3). 
The aqueous solution was then basified with concentrated ammonia and extracted
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with chloroform (4 x 50 cm3). The chloroform extract was washed with saturated 
sodium chloride solution and dried ( Na2S04 ) and evaporated to give a residue 
(0.7g) which on examination (TLC) was found to contain five or more compounds 
and none corresponding to oxymorphone (105).
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4.6 Separation of noroxycodone from a mixture of it with oxycodone
1. Attempted separation using polysiloxane film
A glass cell which consists of two compartments separated by a polysiloxane film 
(12, Crown-4-polyorganosiloxane DD 300 ) was set up. A solution of a mixture of 
oxycodone and noroxycodone prepared by dissolving 0.1 g of the mixture in 10 cm3 
of 0.01M hydrochloric acid, was taken in one compartment while the other 
compartment was filled with a 0.01M solution of potassium hydroxide. The solution 
was left undisturbed for 2 days. It was noted that noroxycodone was not transported 
through the membrane to the KOH solution even after leaving for 2 days.
2. Separation using 12-crown-4 functionalisedpolysiloxane
An aqueous solution of a mixture of oxycodone and noroxycodone containing 1 mg 
mixture per 1 cm3 of 0.01M hydrochloric acid was shaken vigorously with 
polysiloxane liquid ( 12-crown-4-polyorganosiloxane ), (1 g). The mixture was 
allowed to separate overnight. The aqueous layer was analysed by HPLC. The 
solution of the mixture of oxycodone and noroxycodone before the treatment of the 
polymer was also analysed and it was found that there was a 6% decrease in the 
peak area of noroxycodone after polymer treatment while the oxycodone 
concentration was not affected.
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4.7 Synthetic Routes to Normorphine, Hydromorphone and Noroxymorphone
3,6-Bis (itn-butyldimethylsilyI)-morphine (154)
A solution of morphine (1), ( 0.57 g, 2 m mol) in DMF (5 cm3) was stirred with 
imidazole (0.75 g, 10 mmol, 2.5 equivalent per mole of OH ) and TBDMS chloride 
( 0.9 g, 6 mmol, 1.5 equivalent per mole of OH ) under N2 at room temperature for 
about 15 hours. When morphine reacted completely ( followed by TLC ) and a 
single spot on TLC plate corresponding to the title compound was resulted, the 
reaction mixture was partitioned between chloroform and water and extracted with 
chloroform ( 4 x 20 cm3 ). The chloroform extract was washed with water, dried 
(Na2S04) and evaporated under reduced pressure first and then under high vacuum 
to give the title compound (154), ( 1.01 g, 98% yield ) as a white solid. It was 
crystallised from ethanol - water mixture ( 3:1 ). Rf = 0.58 ( CHC13 : CH3OH = 9 :1  
); m.p. 119 - 120° ( lit,148 119 -119.5°); \)m„ : 3140,2880, 2834,1618,1570,1432, 
1370, 1340, 1320, 1250 - 1160 (br), 1115, 1090, 970, 940, 880 and 820 cm 1; 5H 
(CDC13) : 0.10,0.125,0.134 and 0.21 (4  x 3H, 4 x s, 4 x Si-CH3 ), 0.93 and 0.97 (2  
x 9H, 2 x s, 2 x Si-rBu ), 1.84 ( 1H, dm, 7gem = 12.5 Hz, 15-Ha), 2.01 ( 1H, td , /  = 
12.6 and 5.7 Hz, 15-Hp), 2.29 ( 1H, dd, 7gem = 18.5 Hz and / 10,9 = 6.2 Hz, 10-Ha),
2.42 ( 1H, td, 7 = 12.1 and 3.3 Hz, 16-Ha )- 2-43 ( 3H, s, N-CH3 ), 2.53 ( 1H, m, 
16-Hp ), 2.60 ( 1H, m, 14-H), 3.02 ( 1H, d, 7gem = 18.5 Hz, 10-Hp ), 3.34 ( 1H, q, 
7910 = 6.3, J9M = 3.2 Hz, 9-H ), 4.21 ( 1H, m, 765 = 5.7 Hz, 6-H ), 4.66 ( 1H, dd, 75>6 
= 5.7 Hz and 75>7 = 1.3 Hz, 5-H), 5.23 ( 1H, dt, JtJ  = 9.5 Hz, 78,14 = 2.8 Hz, 8-H ), 
5.50 ( 1H, dm, 77-8 = 9.7 Hz, 776 = 3.3 Hz, 7-H ), 6.40 - 6.80 ( 2H, dd, 7 =  8.1 Hz,
1-H and 2-H ); m/z (%): ( E .I.) 73 (100), 456 ( 42, [ M - Bu ]+ ), 413 (40), 513 (12, 
M+ ); ( Low E .I.) 513 (100, M+ ), 456 (80), 413 (20). Found: C = 67.5, H = 9.4 and 
N = 2.77%, calculated fo r: C29H47Si2N 03 : C = 67.78; H = 9.2; N = 2.73%.
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3-(tert-Butyldimethylsilyl)-morphine (155)
A solution of sodium ethoxide was prepared by dissolving dry sodium metal (0.13 
g, 1.1 equivalent per mole of morphine) in absolute ethanol (40 cm3). Morphine (1) 
( 1.42 g, 5 mmol ) was dissolved in this solution and the resulting solution was 
evaporated under reduced pressure. The residue was dissolved in benzene (20 cm3) 
and evaporated again to give a white powder. This was dissolved in dry THF (40 
cm3) and to this solution TBDMSC1 ( 1.10 g, 7.3 m m ol) dissolved in dry THF (5 
cm3) was added slowly under nitrogen. The mixture was left stirring overnight under 
nitrogen at room temperature. The solvent was then evaporated, the residue was 
dissolved in chloroform, washed with water, dried ( Na2S04 ) and evaporated to 
give the title compound (155), ( 1.98 g, 99% yield ). It was crystallised from ethyl 
acetate to give colourless needles. M.p. 201 - 203°C (decomp.); Rf = 0.35 ( CHC13 : 
MeOH = 9 :1 ) ;  umax 3540, 3360, 2905, 2840, 2280, 1595,1440, 1380, 1320, 1270 - 
1170 (br), 1108,1055,960,875 and 825 cm 1; $h( CDC13 ) 0.16 and 0.19 (2  x 3H, 2 
x s, 2 x Si-CH3 ), 0.98 ( 9H, s, Si-r-Bu), 1.8 - 2.6 ( 4H, m, 15-H2 and 16-H2 ), 2.28 ( 
1H, dd, / gem = 18.7 Hz and / 10,9 = 6.2 Hz, 10-1^), 2.44 ( 3H, s, N-CH3 ), 2.60 ( 1H, 
m, 14-H ), 2.81( 1H, br.d, 6-OH ), 3.02 ( 1H, d, /  = 18.6 Hz, 10-Hp ), 3.40 ( 1H, q, 
/ 9>10 = 6.4 Hz, 9-H ), 4.16 ( 1H, m, 6-H ), 4.85( 1H, dd, J5 6 = 6.0 Hz and J5J = 1.1 
Hz, 5-H ), 5.30 ( 1H, m, 8-H ), 5.70 ( 1H, m, 7-H ), 6.40-6.60 ( 2H, AB system, J  = 




A solution of 3,6-disilyl ether of morphine (154), ( 0.26 g, 0.51 mmol ) in
1,2-dichloroethane (6 cm3) and vinyl chloroformate (0.2 cm3, 0.25 g, 5 equi.) were 
refluxed under nitrogen for 3 days. When the reaction was complete ( followed by 
TLC ), the solution was evaporated under reduced pressure to give a white solid. It 
was purified by column chromatography on silica eluting with chloroform to get the 
title compound (157), (0.28 g, 97% yield). Rf = 0.90 ( CHC13 : CH3OH = 9 : 1); 5H 
( CDC13 ) :  0.097,0.12,0.14 and 0.21 (4  x 3H, 4 x s, 4 x Si-CH3 ), 0.93 and 0.97 (2  
x 9H, 2 x s, 2 x Si-f-Bu ), 1.90 - 2.00 ( 2H, m, 15-H2 ), 2.52 ( 1H, m, 14-H), 2.75 ( 
1H, m, 10-Ha ), 2.89 ( 1H, d, /  = 18 Hz, 10-Hp ), 3.10 ( 1H, m, 16-Ha  ), 3.48 ( 1H, 
m, 16-Hp ), 4.12 ( 1H, m, 9-H ), 4.20 ( 1H, m, 6-H ), 4.68 ( 1H, dm, /  = 5.7 Hz, 5-H 
), 4.75 - 5.00 ( 2H, m, vinyl- CH=CH2 ), 5.26 ( 1H, m, 8-H ), 5.65 ( 1H, m, 7-H ),
6.42 - 6.62 ( 2H, q, AB system, J  = 8.2 Hz, 1-H and 2-H ), 7.20 - 7.30 ( 1H, m, 
vinyl- CH=CH2 ); mlz (%): ( E .I.) 512 ( 50, M - f-Bu ), 569 ( 8, M+ ), 526 ( 5, M - 
C2H3CO ); ( C .I.) 570 (90, [M+HT), 512 (95)
Normorphine from 3,6-bis(tert-butyldimethylsilyl)-N-vinyloxycarbonylnormorphine 
(157)
Method 1.
The compound (157), ( 0.28 g, 0.49 mmol ) was dissolved in dichloromethane (5 
cm3) and dry hydrogen chloride gas was passed for 1 hour. The solution was then 
evaporated and the residue was stirred with methanol (5 cm3) at 45°C for 2 hours. 
The solution was evaporated to get the title compound (94). It was purified by 
dissolving in 1% sodium hydroxide solution, acidifying the solution with acetic acid
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and then making basic with concentrated ammonia. The crystals of normorphine 
were collected by filtration washed with ice-cold water and dried in vacuum. (0.13 
g, 97% ) Rf = 0.05 ( CHC13 : MeOH = 9 : 1 ) Rf = 0.62 ( CHC13 : MeOH = 1 : 1 )  
m.p. = 274 - 275° ( lit.,110 276 - 277°) 3220, 3180,1300 cm 1: 8h ( CD3O D ) :
2.11 - 2.35 ( 2H, m, 15-H2 ), 2.87 ( 1H, m, 14-H), 3.0 - 3.20 ( 2H, m, 16-H2 ), 3.02 ( 
1H, d, 10-Ha), 3.30 ( 1H, m, 9-H ), 3.34 ( 1H, d, /  = 18.0 Hz, 10-Hp ), 4.26 ( 1H, 
m, 6-H ), 4.92 ( 1H, dd, /  = 5.1 Hz, 5-H ), 5.32 ( 1H, dm, /  = 9.9 Hz, 8-H ), 5.76 ( 
1H, d m ,/=  10.1 Hz, 7-H ), 6.57 ( 1H, d,/  = 8.2 Hz, 1-H), 6.64 ( 1H, d , / =  8.1 Hz,
2-H ); mil (%): ( E .I.) 271 ( 100, M+ ), 201 (40), 150 (40), 148 (38); ( C .I.) 254 ( 
100, M - O H ), 271 (82, M+), 272 ( 40, M+H).
Method 2
A solution of 3,6-bis (TBDMS)-N-vinyloxycarbonyl normorphine (157), (0.2 g, 0.35 
mmol) in 5cm3 of methanol containing 3 drops of concentrated hydrochloric acid 
was heated under reflux for 2 hours ( TLC examination showed the cleavage of silyl 
groups and carbamate group complete ). The solution was evaporated and 
normorphine obtained was purified as explained above. ( Yield = 0.092 g, 96% )
Normorphine using 1-chloroethyl chloroformate as a demethylating agent
A mixture of 3,6-bis (TBDMS)-morphine (154), ( 0.26 g, 0.51 mmol ) in
1,2-dichloroethane (6 cm3) and 1-chloroethyl chloroformate ( 0.5 cm3, 0.66 g, ca. 9 
equivalents ) was heated under reflux in an atmosphere of nitrogen overnight. More 
1-chloroethyl chloroformate (0.5 cm3) was added and continued heating for 2 more 
days. The reaction was followed by TLC. Rf of 3,6-bis (TBDMS)- 
N-(l-chloroethoxycarbonyl normorphine = 0.89 ( CHC13 : CH3OH = 9 : 1 ) .  When 
the reaction was complete, the reaction mixture was evaporated and the residue was 
heated under reflux with 10 cm3 of methanol containing 3-4 drops of concentrated
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hydrochloric acid for an hour. The solvent was evaporated off under reduced 
pressure and the residue of normorphine was purified as described above. ( Yield = 
0.1 lg, 80%)
Preparation o f N-bromoacetamide and its reaction with 3,6-b\s(tert-butyl- 
dimethylsilyl)-morphine (154)
(a) N-Bromoacetamide
To a solution of acetamide ( 2.0 g, 0.034 m ol) in bromine ( 5.4 g, 0.034 m ol) at 0 - 
5°C, an ice cold aqueous solution of potassium hydroxide (50%) was added slowly, 
in small portions, stirring and cooling until the colour became light yellow. The 
mixture was allowed to stand at 0 - 5°C for 3 hours. It was then treated with solid 
sodium chloride (4g) and chloroform (20 cm3) and warmed on a steam bath for 2-3 
minutes. The clear red solution was decanted off and the residue was extracted with 
chloroform twice more ( 20 cm3 and 10 cm3 ). The combined extracts were dried 
(Na2S04), filtered and mixed with hexane (50 cm3) and chilled for 2 hours. The 
colourless crystals of N-bromoacetamide was collected with suction at the pump, 
washed with hexane and dried. (Yield = 1.8 g, 40%)
(b) 1 -Bromo-3,6-bis( tert-butyldimethylsilyl)-morphine
The compound (154), ( 0.26 g, 0.5 mmol) dissolved in methanol (5 cm3) was kept 
cooled at 0 - 5°C while a solution of N-bromoacetamide ( 0.09 g, 0.65 mmol) in 
methanol (2 cm3) was added very slowly (30 mins). The mixture was left stirring at 
15°C for 3 hours. The reaction mixture was evaporated and the residue was column 
chromatographed on silica using chloroform - methanol solvent system to yield
l-bromo-3,6-bis (TBDMS)-morphine (164), ( 0.098 g, 33% ) and the unreacted
-145-
compound (154), (0.05 g). Rf = 0.75 ( CHC13 : CH3OH = 9 : 1 ); ^  ( CDC13 ) : 
0.096,0.12,0.15 and 0.20 ( 4 x 3H, 4 x s, 4 x Si-CH3 ), 0.91 and 0.96 (2  x 9H, 2 x s, 
2 x Si-r-Bu ), 1.98 ( 1H, m, 15-Ha), 2.60 ( 1H, m, 15-Hp ), 2.80 ( 1H, m, 16-Ha ), 
2.81 ( 3H, s, N-CH3 ), 2.83 ( 1H, dd, /  = 18.6 Hz, 10-Ha), 2.92 ( 1H, d, /  = 18.0 Hz, 
10-Hp), 3.17 ( 1H, m, 16-Hp ), 3.38 ( 1H, br.s, 14-H), 3.90 ( 1H, m, 9-H), 4.26 ( 1H, 
m, 6-H), 4.75 ( 1H, d, /  = 5 Hz, 5-H), 5.17 ( 1H, dt, 8-H), 5.70 ( 1H, m, 7-H ), 6.84 
( 1H, s, 2-H ); m!z ( Low E.V.E.I.) 536 (100%, M - f-Bu), 534 (90), 591 (25, M+ ), 
593 (25).
Preparation of iodosobenzene and attempted oxidation of 3,6-bis(tert-butyl- 
(Hmethylsilyl)-morphine (154) with iodosobenzene.
(1) Preparation o f iodosobenzene
An aqueous solution of sodium hydroxide ( 3 M, 15 cm3 ) was added slowly (5 
mins) to finely ground iodosobenzene diacetate ( 3.2 g, 0.01 mol ) with vigorous 
stirring. The lumps of solid were triturated with a glass rod and the mixture was 
stirred for 1 hour. Water (10 cm3) was added to the mixture, stirred vigorously and 
filtered at the pump. The wet solid was triturated again with water (20 cm3), filtered, 
washed with water (20 cm3) and dried by maintaining suction. The dried solid was 
triturated with chloroform (10 cm3), filtered and air-dried to give pure 
iodosobenzene (1.75 g, 80%).
(2) Attempted oxidation of morphine disilyl ether (154) with iodosobenzene.
Borontrifluoride-diethyl ether ( 0.3 g, 2 mmol ) and then 3,6-bis 
(TBDMS)-morphine (154) ( 0.50 g, 1 mmol) were added to a stirred, ice cold (0 - 
5°C) suspension of iodcfbenzene ( 0.24 g, 1.1 mmol ) in a mixture of
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dichloromethane (10 cm3) and water (10 cm3). The mixture was stirred at this 
temperature for 2 hours and then at room temperature for 2 hours. The mixture was 
neutralised with solid sodium hydrogen carbonate and extracted with chloroform. 
The chloroform extract on analysis was found to contain the starting material and no 
oxidation product of silyl morphine.
Oxidation o f 3-(tert-butyldimethylsiliyl)- morphine (155) to 3-(tert-butyl- 
dimethylsilyl)-morphinone (165)
(1) With manganese (IV) oxide.
A solution of 3-(TBDMS)-morphine (155), ( 0.28 g, 0.7 mmol) in chloroform (50 
cm3) was stirred with activated manganese (IV) oxide ( Aldrich ) ( 2.8 g, 10 weight 
equivalents) at room temperature for 20 minutes. The mixture was filtered through a 
pad of silica gel ( 2-3 mm thick, taken in a sintered glass ), washed with warm 
chloroform and the filtrate and washings were evaporated to give 3-(TBDMS)- 
morphinone (165), as an oil. It was purified further by flash column chromatography 
on silica with dichloromethane - methanol solvent mixture ( 98 : 2 ). Yield = 0.26 g, 
91%; Rf = 0.43 ( CHC13 : CH3OH = 9 : 1 ) ;  umax: 3670, 3535, 3300 - 3000 (br), 
2915, 2810,1720,1667,1600, 1490,1430,1320,1270 - 1170 (br), 980, 935 and 832 
c m 1; 5h ( CDC13 ) :  0.1 and 0.18 (2  x 3H, 2 x s, 2 x Si-CH3 ), 0.97 ( 9H, s, Si-r-Bu 
), 2.40 ( 1H, dd, J  = 18.6 and 5.1 Hz, 10-Ha ), 2.46 ( 3H, s, N-CH3 ), 2.57 ( 1H, m, 
14-H ), 3.09 ( 1H, d, /  = 18.7 Hz, 10-Hp ), 3.41 ( 1H, m, 9-H ), 4.66 ( 1H, s, 5-H ),
6.07 ( 1H, dd, / 8 7 = 10.3 and / 814 = 2.8, 8-H), 6.63 ( 1H, d, /  = 10.4 Hz, 7-H ), 6.52 
- 6.64 ( 2H, dd, J  = 8.2 Hz, 1-H and 2-H ); m/z (%): ( Low E.V. E .I.) 397 ( 100, M+ 
), 340 ( 90, [M - r-Bu]+).
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(2) With selenium dioxide.
Selenium dioxide ( 0.22 g, 0.2 mmol) was added to a mixture of dioxan (10 cm3) 
and water (0.8 cm3) and stirred at 40°C until dissolved. 3-(TBDMS)-morphine 
(155), (0.4 g, 0.1 mmol) was introduced to the above solution and the mixture was 
heated under reflux for 2 hours. The mixture was filtered, evaporated under reduced 
pressure and the residue was column chromatographed on silica with chloroform - 
methanol solvent mixture to yield 3-(TBDMS) moiphinone (165), ( 0.06 g, 14.6% 
yield) and unchanged 3-(TBDMS)-morphine (155), (0.22 g).
(3) With selenium oxide and tert-butyl hydroperoxide.
A mixture of 3-(TBDMS)-morphine (155) ( 0.101 g, 0.25 mmol ) in 
dichloromethane (12 cm3), selenium dioxide ( 0.15 g, 1.4 mmol ) and rm-butyl 
hydroperoxide (1 cm3, 3 M solution in octane ) was left stirring at room temperature 
for one day. TLC examination indicated no oxidation. So the mixture was heated 
under reflux for two days. The volatiles were removed under reduced pressure, the 
residue was extracted with chloroform, washed with sodium hydrogen carbonate 
solution, dried ( Na2S04 ) and evaporated. The product mixture was column 
chromatographed on silica with chloroform - methanol to yield 3-(TBDMS)- 
14-hydroxymorphinone (166), ( ca. 0.01 g, <10% yield ) and 3-(TBDMS)- 
morphinone (165), ( 0.045g, 43% yield ). About 10% unreacted silyl morphine ether 
(155) was also recovered.
(4) With tetrapropyl ammonium perruthenate and N-methylmorpholine N-oxide.
To a stirred mixture of 3-(TBDMS)-morphine (155), ( 0.18 g, 0.45 mmol ), 
N-methylmorpholine N-oxide ( 0.8 g, 0.7 mmol, 1.5 equivalents) and powdered 4 A
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molecular sieves (0.20 g) in dry dichloromethane (3 cm3) was added solid TPAP (10 
mg, 5 mol%) under nitrogen at room temperature. The mixture was then left stirring 
for 2 hours. The mixture was passed through a short column of silica ( 5 cm length, 
1 cm diameter ) and eluted with ethyl acetate. The solution was evaporated to give 
3-(TBDMS)-morphinone (165), ( 0.16 g, 86% yield ) which was
chromatographically pure.
3-(tert-Butyyldimethylsilyl)-dihydromorphinone ( 175, 3-tert-butyldimethylsityl- 
hydromorphone )
Hydrogen gas was passed through a mixture of 3-(TBDMS)-morphinone (165), 
(0.13 g, 0.33 mmol) in absolute ethanol (30 cm3) and Pd/C catalyst ( 10%, 0.07 g ) 
for 1 hour. The mixture was filtered, the residue was washed with ethanol and the 
filtrate was evaporated to give the title compound ( 0.12 g, 92% ) as a glassy solid. 
Rf = 0.41 ( CHC13 : CH3OH = 9 : 1 ) .  This product without further purification is 
converted to hydromorphone (93) as explained below.
Hydromorphone (93)
3-(TBDMS)-hydromorphone (175), ( 0.10 g, 0.25 mmol) dissolved in dry THF (2 
cm3) was stirred with tetrabutyl ammonium fluoride ( 0.5 cm3, 1M solution in THF) 
under N2 at room temperature for 30 minutes. When the reaction was complete 
(followed by TLC) the solution was evaporated, the residue was dissolved in 
minimum volume of dilute hydrochloric acid, cooled to 0°C and basified with 
concentrated ammonia. The white precipitate of hydromorphone formed was 
filtered, washed with cold water and dried. It was crystallised from ethanol. Yield = 
0.064g, 90%. R, = 0.21 ( CHC13 : MeOH = 9 : 1 ) ;  m.p. = 265 - 266°C (lit.,172 266 -
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267°C); \)max 3380, 2660, 1710, 1615 cm 1; ^  (D20) ( 93.HC1) 1.16 ( 1H, m, 8-Ha 
), 1.98 ( 2H, m, 15-1^ and 15-Hp), 2.33 - 2.40 ( 2H, m, 7-Ha and 8-H p), 2.65 (1H, 
td, /  = 14.3,4.8 Hz, 7-Hp), 2.77 - 2.89 ( 2H, m, 10-Ha, 16-Ha), 2.93 ( 3H, s, N-CH3 
), 3.10 - 3.35 ( 3H, m, 14H, 16-Hp, 10-Hp ), 4.01 ( 1H, br.s, 9-H ), 5.08 ( 1H, s, 5-H 
), 6.75 - 6.82 ( AB system, 2H, J  = 8.2 Hz, 1-H and 2-H ); m/z (%): ( E .I.) 285 (90, 
M+ ), 228 (25); ( C .I.) 286 (100 [M+H]+ ), 285 (60, M+)
3-(tert-Butyldimethylsilyl)-14-hydroxymorphinone (166)
3-(TBDMS)-morphine (155), ( 0.62 g, 1.56 mmol ) dissolved in chloroform (80 
cm3) was stirred with activated manganese (TV) oxide ( 6.0 g, 10 weight equivalent) 
at 38-40°C for 15 minutes. TLC on silica with chloroform - methanol (9:1 ) as 
solvent system showed the conversion of the compound (155), ( Rf = 0.35 ) to 3-silyl 
morphinone (165), ( Rf = 0.46 ) almost complete. Silica gel ( 1.8 g, 3 weight equi., 
Merck No 7736, Type 60H ) was then added and continued stirring vigourously at 
the same temperature ( 38 - 40°C ) for 3 hours. When the oxidation to 3-silyl- 
14-hydroxyl morphinone (166) was complete ( followed by TLC, Rf = 0.55 ) the 
mixture was filtered through a sintered glass and the residue washed with warm 
chloroform (200 cm3) containing 1% methanol. The filtrate on evaporation gave the 
title compound (166), ( 0.38 g, 59.2% ) as an off-white solid. It was crystallised 
from ethyl acetate as colourless plates. Rf = 0.55 ( CHC13: CH3OH = 9:1 ); m.p. = 
222-224°C ( Ethyl acetate ); \)max: 3500, 3340 (br), 2905, 2840, 1740, 1700,1670, 
1590,1480,1425,1380,1345,1320,1260-1180 (br), 1100,1030,990,975,940, 880 
and 830 cm 1; 5h ( CDC13 ): 0.10 and 0.16 (2  x 3H, 2 x s, 2 x Si-CH3 ), 0.95 ( 9H, s, 
Si-r-Bu ), 1.63 - 2.57( 4H, m, 15-Ha, 15-Hp, 16-Ha , 16-Hp ), 2.35 ( 1H, dd, J  = 
18.7, 6.0 Hz, 10-Ha  ), 2.44 ( 3H, s, N-CH3 ), 3.03 ( 1H, d, J  = 5.9 Hz, 9-H ), 3.20 ( 
1H, d, /  = 18.7 Hz, 10-Hp ), 4.67 ( 1H, s, 5-H ), 6.16 ( 1H, d, /  = 10.1 Hz, 8-H ),
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6.61 ( 1H, d, /  = 10.1 Hz, 7-H ), 6.53 - 6.64 ( 2H, AB system, J  = 8.0 Hz, 1-H and
2-H ); 8h (DMSO): 5.4 ( 1H, br.s, 14-OH ); 8C ( CDC13 ): 4.77 ( Si-CH3 ), 4.64 
(Si-CH3), 18.23 ( Si-CNte, ), 22.48 (C-15), 25.62 ( Si-C(CH3)3 ), 29.55 (C-16), 
42.55 ( N-CH3 ), 45.12 (010), 46.71 (013), 64.16 (09 ), 67.79 (014), 86.86 (05 ), 
119.46 (08 ), 122.54 (07 ), 125.46 (O il) , 130.55 (012), 134.67 (O l), 137.85
(0 4 ), 146.35 (03 ), 147.45 (02), 194.03 ( C=0 ); mlz (%): ( Low E .I.) 413 ( 100, 
M+ ), 356 ( 90, [M - f-Bu]+ ). [ Found; C, 66.5; H, 7.5; N, 3.35. Required for 
C23H31SiN04 ; C, 66.8; H, 7.5; N, 3.4% ].
Attempted oxidation of the morphinone (165), to the 14-hydroxymorphinone (166)
(1) Oxidation with singlet oxygen
Oxygen gas was bubbled through a mixture of 3-(TBDMS)-morphinone (165), (0.12 
g, 0.3 mmol) dissolved in dichloromethane - methanol mixture ( 9 : 1; 50 cm3 ) and 
Rose Bengal catalyst ( 10 mg, 0.01 mmol ), maintained at a temperature of 10 - 
12°C. The mixture was irradiated with a visible lamp (120V, 650W) for 1 hour. 
Thiourea was then added to the mixture and stirred for 12 hours. The solvents were 
evaporated off and the residue was extracted with chloroform. The chloroform 
extract was washed with water, dried ( Na2S04 ) and evaporated to give a residue 
which contained no 14-hydroxymorphinone (166).
(2) Oxidation with selenium dioxide and tert-butyl hydroperoxide.
A solution of 3-(TBDMS) morphinone (165), ( 0.10 g, 0.25 mmol ) in 
dichloromethane (1 cm3) was added slowly to a stirred solution of selenium dioxide 
(10 mg, 0.1 mmol) and terf-butyl hydroperoxide ( 1 cm3, 3M solution in octane ) in
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dichloromethane (5 cm3). The mixture was left stirring overnight at room 
temperature. TLC showed that no appreciable amount of the 14-hydroxymorphinone 
was formed.
3-(tert-Butyldimethylsilyl)-morphinone dienol acetate (168)
A mixture of 3-(TBDMS)-morphinone (165), ( 0.10 g, 0.25 m mol), fused sodium 
acetate (20 mg) and acetic anhydride (3 cm3) was heated under reflux under N2 for 2 
hours. The volatiles were removed under high vacuum and the residue was mixed 
with water and extracted with chloroform to give the title compound (168). It was 
purified by flash column chromatography on silica with chloroform - methanol (98 : 
2) as solvent to yield the dienol acetate, ( 0.094 g, 84% ). Rf = 0.73 ( CHCI3 : 
CH3OH -  9 : 1); 5h ( CDQ3 ) 2.15 ( 3H, s, COCH3 ), 2.51 ( 3H, s, N-CH3 ), 5.4 ( 
1H, s, 5-H ), 5.52 ( 1H, d, /  = 6.5 Hz, 8-H ), 5.69 ( 1H, d, /  = 6.5 Hz, 7-H ), 6.5 - 6.6 
( 2H, dd, /  = 8.5 Hz ); mlz (%): ( C.I. ) 382 ( 100, M - f-Bu ), 441 (42), 440 ( 40, 
M+H), 439 (12, M+).
Attempted oxidation o f the dienol acetate (168) to 3-tert-butyldimethylsilyl)- 
14-hydroxymorphinone (166)
The dienol acetate (168) (0.094 g, 0.21 mmol) was dissolved in a mixture of formic 
acid (98%, 0.5 cm3 ) and sulphuric acid (1%, 2 cm3 ) and to this mixture was added 
hydrogen peroxide ( 30%, 0.5 cm3 ). The mixture was heated at 40°C for 6 hours, 
cooled, diluted with water and made basic with concentrated ammonia. The mixture 
was extracted with chloroform which on evaporation gave a residue (0.05 g). The 
residue on analysis was found to be some decomposition product of the substrate 




A mixture of the hydroxymorphinone (166), ( 0.20 g, 0.48 mmol ) dissolved in 
absolute ethanol (50 cm3) and Pd/C ( 10%, 0.1 g ) was stirred under hydrogen for 2 
hours. The mixture was filtered and the residue was washed with ethanol. The 
filtrate and the washings were evaporated to give the dihydromorphinone (169), 
(0.20 g, quantitative yield). It was crystallised from ethyl acetate, m.p. 133 - 135°C; 
Rf = 0.49 ( CHC13 : CH3OH = 9 : 1 ) ;  a w  3650, 3380 (br), 2900, 2800, 1720, 
1670,1592,1430,1310,1270-1180 (br), 1095,1020,985,923, 880 and 825 cm 1; ^  
( CDCI3 ): 0.19 and 0.26 ( 2 x 3H, 2 x s, 2 x Si-CH3 ), 0.98 ( 9H, s, Si-f-Bu ), 1.52 
(1H, m, 15-Ha ), 1.67 ( 1H, m, 8-Ha ), 1.97 ( 1H, m, 15-Hp ), 2.20 - 2.60 ( 3H, m,
7 - ^ ,  7-Hp and 8-Hp ), 2.53 ( 3H, s, N-CH3 ), 2.67 ( 1H, m, 16-Ha ), 2.68 ( 1H, dd, 
J  = 18.5, 5.5 Hz, 10-Ha), 3.02 ( 1H, m, 16-Hp ), 3.15 ( 1H, d, /  = 18.5 Hz, 10-Hp ), 
3.20 ( 1H, m, 9-H ), 4.63 ( 1H, s, 5-H ), 6.55 - 6.66 ( 2H, q, AB system, J  = 8.2 Hz, 
1-H and 2-H); mlz (%): ( E.I.) 358 (100, [M - r-Bu]+), 315 (45), 415 (20, M+ ).
Attempted 14-OH protection o f the oxymorphone (169) as tert-butyldimethyl- 
sityl-ether
a) With TBDMSCl
A solution of 3-(TBDMS)-oxymorphone (169), ( 0.32 g, 0.77 mmol ) in DMF (5 
cm3) was stirred with TBDMSCl (0.40 g, 2.6 mmol, 3 equivalents) and imidazole (
0.14 g, 1.9 mmol, 2.5 equivalents ) under nitrogen at room temperature. TLC taken 
after 4 hours indicated no silylation of the hydroxy group. So the mixture was left 
stirring overnight and found that no silylation had taken place. The starting material
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was recovered from the reaction mixture.
b) With TBDMS perchlorate
A mixture of 3-TBDMS-oxymorphone (169), ( 0.42 g, 1 mmol ), TBDMS 
perchlorate (0.22 g, 1 mmol) and pyridine (0.08 g, 1.1 mmol) in dry acetonitrile (5 
cm3) was stirred under nitrogen at room temperature for 2 hours. The reaction 
mixture was then poured into a mixture of saturated sodium bicarbonate solution and 
chloroform. The chloroform layer was washed, dried and evaporated under high 
vacuum to give a residue which was found to be the starting material.
c) With TBDMS triflate
A mixture of 3-TBDMS-oxymorphone (169), ( 0.4 g, 1 mmol), dry 2,6-lutidine ( 2 
equi.) and TBDMS triflate ( 0.4 g, 1.5 equi. ) in dichloromethane was stirred under 
nitrogen for 1 hour. TLC examination of the reaction mixture showed that no 
reaction had taken place.
3-(tert-Butyldimethylsilyl)-14-acetoxydihydromorphinone (170)
A mixture of 3-silyl-14-hydroxy dihydromorphinone (169), ( 0.62 g, 1.4 mmol) and 
acetic anhydride (10 cm3) was heated under reflux for 1.5 hours. The volatiles were 
removed under high vacuum, the residue was dissolved in a mixture of water and 
chloroform, basified the mixture with ammonia to pH 9 and extracted with 
chloroform. The organic extract was dried ( Na2S04 ) and evaporated to give a 
brown residue which was column chromatographed on silica using chloroform to 
elute the title compound (170), (0.63 g, 92%). It was recrystallised from ethanol to 
give white shiny crystals. Rf = 0.60 ( CHC13 : CH3OH = 9 : 1 ) ;  m.p. 178 - 179°C;
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XW  .cm 1: 2860,2792, 2250,1690, 1575,1403,1330,1210 -1160 (br), 1130,1070, 
960,920 and 805; 5h ( CDC13 ): 0.18 and 0.26 (2  x 3H, 2 x s, 2 x SiCH3 ), 0.99 (9H, 
s, Si-r-Bu), 1.47 ( 1H, dd, /  = 11.7, 4.2 Hz, 15-Ha ), 1.66 ( 1H, td, /  = 14.3, 4.0 Hz,
8-Ha )» 2 00 ( 1H, dd, /  = 18.5 and 5.6 Hz, 10-Ha ), 2.18 ( 3H, s, N-CH3 ), 2.25 ( 
1H, dd, /  = 11.8 and 3.4 Hz, 15-Hp ), 2.32 ( 3H, s, COCH3 ), 2.40 - 2.55 ( 3H, m, 
7-Ha, 7-Hp and 8-Hp), 2.58 ( 1H, dd, /  = 14.8 and 5.5 Hz, 16-Ha ), 2.79 ( 1H, m, J  
= 14.3 and 2.7 Hz, 16-Hp ), 3.18 ( 1H, d, J  = 18.5 Hz, 10-Hp ), 4.16 ( 1H, d, /  = 5.3 
Hz, 9-H ), 4.58 ( 1H, s, 5-H ), 6.55 - 6.66 ( 2H, dd, /  = 8.2 Hz, 1-H and 2-H ); mlz 
(%): ( Low E.V. E.I. ) 400 (100, [M - f-Bu]+), 457 (50, M+ ).
N-Vinyloxy carbonyl-3-(tert-butyldimethylsilyl)-14-acetoxydihydronormorphinone
(171)
A solution of 3-(TBDMS)-14-acetoxydihydromorphinone (170), (0.30 g, 0.66 mmol 
) in 1,2-dichloroethane (10 cm3) was heated under reflux with vinyl chloroformate 
(0.3 cm3, 0.38 g, 5 equi.) under nitrogen for 3 days. More vinyl chloroformate (0.2 
cm3 each ) was added after 25 and 50 hours. When the reaction was complete 
(followed by TLC), the volatiles were removed under reduced pressure first and then 
at high vacuum to get the vinyl carbamate (171), ( 0.33 g, 98% ) as an off-white 
solid. It was purified by flash column chromatography on silica with chloroform as 
eluant. Rf = 0.87 ( CHC13 : CH3OH = 9 : 1 ) ;  umax .cm 1 3500 (br), 1698,1640,1600, 
1415, 1360, 1312, 1180 - 1270 (br), 1140, 990, 940, 830; ^  ( CDC13 ): 0.20 and
0.27 (2  x 3H, 2 x s, 2 x Si-CH 3), 1.00 ( 9H, s, Si-r-Bu), 2.12 ( 3H, s, COCH3 ), 4.50 
( 1H, m, 9-H ), 4.62 ( 1H, s, 5-H ), 4.81 ( 1H, m, GH=CH2 )» 5.61 ( 1H, m, CH=CH2 
), 6.59 - 6.72 ( 2H, dd, /  = 8.1 Hz, 1-H and 2-H ), 7.16 - 7.26 ( 1H, m, CH=CH2 >> 
mlz (%): ( C.I. ) 71 (100, C ^ C O ^ , 456 (73, [M - r-Bu]+ ), 514 ( 6, [M+H]+ ), 513 
(5 ,M +).
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Deprotection of tert-butyldimethylsilyl and vinyloxycarbonyl groups
14-Acetoxydihydronormorphinone hydrochloride ( 14-acetylnoroxymorphone 
hydrochloride) (174.HC1)
Method 1
Dry hydrogen chloride gas was passed through a solution of 
N-vinyloxycarbonyl-3-(TBDMS)-14-acetoxydihydronormorphinone (171), ( 0.30 g,
0.58 mmol) dissolved in dichloromethane (5 cm3) for 1 hour. The solution was then 
evaporated and the residue was dissolved in methanol (10 cm3) and heated under 
reflux for 2 hours. The resultant solution on evaporation gave 14-acetyl- 
noroxymorphone hydrochloride ( 174.HC1 ), ( 0.205 g, 95.9% ). This was used 
without further purification to prepare noroxymorphone (106). Rf = 0.72 
(CHCl3:CH3OH = 9:1); 5h ( CD3OD ): 2.31 ( 3H, s, COCH3 ), 2.55 ( 1H, br.s, N-H), 
3.26 ( 1H, m, 9-H ), 4.93 ( 1H, s, 5-H), 6.69 - 6.78 ( 2H, dd, AB system, J  = 8.2 Hz, 
1-H and 2-H).
Method 2
A solution of N-vinyloxycarbonyl-3-(TBDMS)- 14-acetylnoroxymorphone (171), 
( 0.10 g, 0.2 mmol ) in methanol (5 cm3) containing 3 drops of concentrated 
hydrochloric acid was heated under reflux for 1 hour. The resultant solution on 




A mixture of 14-acetylnoroxymorphone hydrochloride (171.HC1), ( 0.20 g, 0.55 
mmol ) and 25% dilute sulphuric acid (2 cm3) was heated at 100 - 102°C under 
nitrogen for 5 hours. The mixture was cooled to 0°C and basified with concentrated 
ammonia. The precipitate was collected by centrifugation and dried. The crude 
product was dissolved in minimum amount of dilute hydrochloric acid, cooled to 
0°C, basified with concentrated ammonia and the precipitate was collected, washed 
with cold water and dried to give noroxymorphone (0.138 g, 88% ). omax ( Nujol,
106.HC1) 3570, 3500 - 3280, 3160,1710,1620,1540,1055,1020,950,910 and 885 
c m 1; 8h ( D20 , 106.HC1) 1.65 ( 1H, dd, / gem = 14.5 Hz and / 10,9 = 4.5 Hz, 10-Ha 
), 1.74 ( 1H, m, 15-Ha ), 2.02 ( 1H, dm, / gem = 14.1 Hz, 15-Hp ), 2.28 ( 1H, dt, / gem 
= 14.8 Hz, 8-Ha ), 2.63 ( 1H, td, / gem = 13.4 Hz and 4.9 Hz, 7-H a), 2.85 ( 1H, td, J  
= 13.2 Hz and 4.2 Hz, 7-Hp ), 2.99 ( 1H, td, /  = 14.8 Hz and 5.1 Hz, 8-Hp ), 3.19 - 
3.32 ( 3H, m, 10-Hp and 16-H2 ), 3.87 ( 1H, m, 9-H ), 4.99 ( 1H, s, 5-H ), 6.75 - 6.82 
( 2H, dd, AB system, /  = 8.3 Hz, 1-H and 2-H ); m/z ( E .I.) 287 ( 100%, M+ ). 202 
(60); ( C.I. ) 288 (100, M + 1), 287 (70)
Noroxymorphone (106) from 3-(tert-butyldimethylsilyl)-14-acetyloxymorphone 
(170) using 1-chloroethyl chloroformate
A mixture of 3-(TBDMS)-14-acetyloxymorphone (170), (0.11 g, 0.24 mmol ) in
1,2-dichloroethane and 1-chloroethyl chloroformate ( 0.5cm3, 4.6 mmol ) was 
heated under reflux under nitrogen for 2 days. ( TLC showed the completion of the 
reaction ). The volatiles were removed under reduced pressure and the residue was 
column chromatographed on silica with chloroform solvent to yield 
N-(l-chloroethoxycarbonyl)-3-(TBDMS)-14-acetylnoroxymorphone (176), ( 0.096 
g, 72.6% ). The carbamate (176) was refluxed with 5 cm3 of methanol containing 3
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drops of concentrated hydrochloric acid for 6 hours. When hydrolysis of 
N-carbamate group and TBDMS groups were completed (TLC) the solution was 
evaporated and the residue was heated under reflux with hydrochloric acid ( 6M, 5 
cm3 ) for 5 hours. The resultant solution was cooled, basified with concentrated 
ammonia and the precipitate of noroxymorphone was collected and purified as 
explained earlier (0.047 g, 68% overall yield).
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